Porcine influenza A virus vaccine

Through the alpha virus RNA replicon particle vaccine encoding multiple influenza A virus NA antigens, the problem of poor protection of existing pig influenza A virus vaccines has been solved, and broad-spectrum protection and vaccine renewal cycle of diverse viruses has been achieved. extend.

CN118976103APending Publication Date: 2024-11-19INTERVET INT BV
View PDF 6 Cites 0 Cited by

Patent Information

Application Number
CN202411075916.3
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2017-12-18
Filing Date
2018-12-17
Publication Date
2024-11-19

AI Technical Summary

Technical Problem

The existing swine influenza A virus (IAV-S) vaccines are difficult to effectively protect the pig herds because the diversity and rapid variability of the virus cause conventional vaccines to fail to match modern strains, resulting in poor protection.

Method used

Develop an alpha virus RNA replicon particle vaccine encoding influenza A virus neuraminidase (NA) antigen, avoiding the containing hemagglutinin (HA) or its antigenic fragments, and using the alpha virus RNA replicon particle vector to encode multiple NA antigens , including NA antigens from different phylogenetic clusters and lineages, forming multi-combination vaccines.

Benefits of technology

Vaccines encoding multiple NA antigens can provide broad-spectrum protection, reduce the negative immunity of maternal antibodies on piglets, prolong the vaccine renewal cycle, and improve the protection ability of diverse viruses.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118976103A_ABST
    Figure CN118976103A_ABST
Patent Text Reader

Abstract

The present invention provides vectors and / or nucleic acid constructs encoding one or more influenza A virus neuraminidase (NA) antigens. The invention also provides vaccines against influenza A virus comprising such vectors and / or nucleic acid constructs. The invention further provides methods of making and using the vaccines, alone or in combination with other protective agents.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] This application is a divisional application of the patent application with application number 201880081694.2 and invention name “Swine Influenza A Virus Vaccine”.

[0002] CROSS-REFERENCE TO RELATED APPLICATIONS

[0003] This application claims priority under 35 U.S.C. §119(c) to U.S. Provisional Application Serial No. 62 / 607,101, filed on December 18, 2017. Technical Field

[0004] The present invention relates to vectors and / or nucleic acid constructs encoding one or more influenza A virus neuraminidase (NA) antigens. The present invention also relates to vaccines against influenza A virus comprising these vectors and / or nucleic acid constructs. The present invention also relates to methods for preparing and using the vaccines alone or in combination with other protective agents. Background Art

[0005] Influenza A virus (IAV) imposes a heavy burden on human and animal health worldwide. IAV is a member of the Orthomyxoviridae family and is divided into different subtypes based on its viral surface glycoproteins hemagglutinin (HA) and neuraminidase (NA). IAV infects poultry, pigs, horses, cats, dogs, marine mammals (e.g., whales), bats, and humans. Wild waterfowl and shorebirds (ducks, geese, swans, and gulls) are natural reservoirs that can be infected by 16 different HA and 9 different NA subtypes [Webster et al., Microbiol Rev 56: 152-179 (1992)]. Recently, two new subtypes, H17N10 and H18N11, have been identified in bats [Tong et al., Proc. Natl. Acad. Sci. 109(11): 4269-4274 (2012) and Mehle, Viruses 6(9): 3438-3449 (2014)]. Interspecies transmission of the virus is most common between wild and domestic waterfowl and between pigs and humans [Nelson and Vincent, 23(3) Trends in Microbiol. 142-153 (2015)]. Mammals infected with IAV show acute respiratory disease, resulting in aerosol virus transmission. In waterfowl and poultry, the virus can replicate in the respiratory tract and intestinal tract and be transmitted through the fecal-oral route.

[0006] One such IAV, swine influenza A virus (IAV-S), is a serious respiratory pathogen of domestic pigs that has proven to be economically costly, particularly to the livestock industry worldwide [Holtkamp et al., The American Association of Swine Veterinarians Annual Meeting (2007)]. In addition, the spread of swine-derived influenza viruses to humans has been well documented and poses a significant public health threat, thus providing a greater incentive to control influenza A viruses in swine herds [Krueger and Gray, Curr Top Microbiol Immunol 370:201-225 (2013)].

[0007] In response to this problem, many pig farmers now vaccinate pigs against IAV-S using commercially available vaccines. However, it is difficult to control IAV-S using conventional vaccines because many different IAV-S strains co-circulate in the field and continue to evolve [Gao et al., J Gen Virol 98(8): 2001-2010(2017)]. The diversity and variability of IAV-S are caused by the genetic structure of the virus. Like other influenza A viruses, IAV-S has genes encoded on 8 RNA segments and a genome replication mechanism that introduces frequent mutations. These genetic characteristics enable IAV-S to adapt rapidly, including avoiding the presence of neutralizing antibodies induced by exposure to previous strains. Therefore, despite containing up to 5 different IAV-S strains, the inactivated virus IAV-S vaccines available on the US market have been proven to be insufficient because new strains have emerged due to continued antigenic drift.

[0008] The classification of influenza A viruses begins with the subtypes of HA and NA, which are the two main glycoproteins on the surface of the virus. The HA protein mediates the attachment and fusion of the virus to the host cell. Antibodies that bind to HA can block: viral attachment, viral replication and reduce or even prevent disease. Neuraminidase is an enzyme that works in the final stage of the influenza virus replication cycle by cleaving newly formed viral particles from the host cell, allowing new progeny viruses to spread and infect other cells. Antibodies that bind to NA limit its enzymatic activity, which can reduce the level of viral transmission and the severity of disease in certain animal models.

[0009] Although human influenza A viruses typically circulate 1 or 2 dominant strains worldwide in a given flu season, more IAV-S strains co-circulate simultaneously, and these strains also vary between geographic regions. IAV-S strains are antigenically variable, but mainly contain H1 or H3 subtypes of HA, and N1 or N2 subtypes of NA. Within each HA and NA subtype of IAV-S, there is further phylogenetic diversity. In the US swine population, there are four major H1 phylogenetic clusters (γ, δ1, δ2, pandemic), two major H3 clusters (cluster IV and human-like), two major N1 clusters (classical, pandemic) and two major N2 clusters (N2-1998 and N2-2002). [See, Anderson et al., Influenza and other Respiratory Viruses 7(Suppl. 4); 42-51 (2013); and Anderson et al., mSphere 1(6)e00275-16: 1-14 (2016)]. In Europe, there are three major H1 lineages (Eurasian avian-like H1, Scottish / 410440 / 1994-like H1, and pandemic 2009-like H1), one major H3 lineage (Ghent / 1 / 1984-like H3), two major N1 lineages (Eurasian avian-like N1, pandemic 2009-like N1), two major N2 lineages (Ghent / 1 / 1984-like N2, Scottish / 410440 / 1994-like N2), and two minor N2 lineages (Italian / 4675 / 2003-like N2, human seasonal-like N2) [Watson et al., J. Virol., 89:9920-9931 (2015); doi:10.1128 / JVI.00840-15].

[0010] Over the years, a variety of vector-based strategies have been used in vaccines in an effort to generate protection against certain pathogens. One such vector strategy includes the use of alphavirus-derived replicon RNA particles (RP) [Vander Veen et al., Anim Health Res Rev. 13(1): 1-9. (2012) doi: 10.1017 / S1466252312000011; Kamrud et al., J Gen Virol., 91(Pt 7): 1723-1727 (2010)], which were developed from several different alphaviruses, including Venezuelan equine encephalitis virus (VEE) [Pushko et al., Virology 239: 389-401 (1997)], Sindbis (SIN) [Bredenbeek et al., Journal of Virology 67:6439-6446 (1993)] and Semliki Forest virus (SFV) [Liljestrom and Garoff, Biotechnology (NY) 9:1356-1361 (1991)]. RP vaccines deliver a replication-defective alphavirus RNA replicon into host cells and express one or more desired antigen transgenes in vivo [Pushko et al., Virology 239 (2):389-401 (1997)]. When compared with some traditional vaccine formulations, RP has attractive safety and efficacy properties [Vander Veen et al., Anim Health Res Rev. 13 (1):1-9. (2012)]. The RP platform has been used to encode pathogenic antigens and is the basis of several USDA-licensed swine and poultry vaccines.

[0011] As described above, commercially available IAV-S vaccines for domestic pigs are generally incapable of protecting herds because these antigens do not match all modern strains circulating in the field [Lee et al., Can J Vet Res 71(3):207-12 (2007); Vincent et al., Vaccine 28(15):2782-2787 (2010)]. Conventional platforms of inactivated viral antigens are limited by regulatory and production factors that limit the ability to rapidly update vaccine strains in response to evolving viral antigenic drift. For conventional inactivated virus IAV-S vaccines, the selection of viral strains is based on HA antigenic properties. Serological evaluation of immune responses is similarly focused on measuring antibodies against HA. The same emphasis on HA antigens also applies to marketed inactivated influenza virus vaccines for humans and other influenza-susceptible animal species (e.g., poultry, horses, dogs). IAV-S vaccines that induce HA inhibition (HI) antibody titers can protect pigs from experimental infection with antigenically similar strains [Kyriakis et al., Vet Microbiol 144(1-2):67-74 (2010)]. However, relatively rapid genetic drift of the HA gene has led to the emergence of new strains that are not functionally inhibited by vaccine-induced HA antibodies.

[0012] Clinical studies have shown a statistically significant correlation between NA-specific antibody titers and reduced incidence of influenza disease in humans [Memoli et al., MBio 7(2):e00417-16. (2016); Monto et al., J Infect Dis 212(8):1191-1199 (2015); Murphy et al., N Engl J Med 286(25):1329-32 (1972)]. Various studies in inbred mice have shown that NA-specific immunization can protect against challenge infection [Brett and Johansson, Virology 339(2):273-80 (2005); Johansson and Kilbourne, Proc Natl Acad Sci USA 91(6):2358-2361 (1994); Kilbourne et al., J Infect Dis 189(3):459-461 (2004)]. Hessel et al. [PLoS One 5(8), e12217 (2010)] found that a vaccine containing a recombinant poxvirus vector encoding IAV-S NA was able to partially induce protection against viral challenge in mice, but the poxvirus vector NA was less effective than an equivalent vaccine encoding the corresponding HA gene. Importantly, however, influenza animal models using mice cannot be used as a reliable predictor of vaccine efficacy because, unlike pigs, poultry, and humans, mice are not a natural host for influenza A viruses [Bodewes et al., Expert Rev Vaccines 9(1):59-72 (2010); Tripp and Tompkins, Curr Top Microbiol Immunol 333:397-412 (2009); Vander Veen et al., Vaccine 30(11):1944-1950 (2012)]. In fact, the virus strain must first be adapted to grow in mice because this species is naturally not susceptible to influenza A virus infection. Accordingly, pathogenesis and disease are represented by weight loss and mortality, which differ from infection parameters in the natural host.

[0013] Similar studies were conducted in chickens, a natural host species for influenza viruses, using virally vectored NA vaccines to protect against challenge infection. Chicken NA immunity only partially protected against infection and was significantly less robust than immunity induced by equivalent vectored HA vaccines [Nayak et al., J Virol 84(5):2408-2420 (2010); Pavlova et al., Vaccine 27(5):773-785 (2009); Sylte et al., Vaccine 25(19):3763-72 (2007)]. Similar results were reported in ferrets, another naturally susceptible host of influenza viruses, which were vaccinated with soluble recombinant NA and / or HA proteins and subsequently challenged with the virus [Bosch et al., J Virol 84(19):10366-103674 (2010)]. Together, these data suggest that NA immunity can only serve to supplement and / or complement the more critical HA immunity. Indeed, it appears that in the absence of hemagglutinin antigen, neuraminidase influenza A virus vaccines are not sufficiently effective to protect against influenza A virus infection or to protect against disease caused by influenza A virus.

[0014] A published study examined the effects of an attenuated pseudorabies virus (PrV) vectored NA vaccine on viral challenge infection in pigs [Klingbeil et al., Virus Res 199:20-30 (2015)]. Notably, the combination of PrV-NA with PrV-HA did not provide a significant improvement over the protection induced by PrV-HA alone. The study data did show that the PrV-NA vaccine, whether administered alone or co-administered with a PrV-HA vaccine, induced serum antibodies against the NA protein. However, despite the production of antibodies, pigs vaccinated with NA showed only a very slight reduction in viral replication (statistically significant on only one sampling day: 4 days post-infection). As expected, pigs vaccinated with the PrV-HA vector alone induced HI antibody responses, but these responses were associated with a more significant reduction in viral shedding (statistically significant starting from days 2-6 post-infection). Indeed, to date, there are indeed no published studies demonstrating that IAV-S vaccines containing and / or encoding influenza A virus neuraminidase antigens can adequately protect pigs against IAV-S infection in the absence of the corresponding hemagglutinin antigen.

[0015] The citation of any reference herein should not be construed as an admission that such reference is available as "prior art" to the present application. Summary of the invention

[0016] Therefore, the present invention provides vectors and / or nucleic acid constructs encoding one or more influenza A virus neuraminidase (NA) antigens. These vectors and / or nucleic acid constructs can be used in immunogenic compositions comprising these vectors. The immunogenic compositions of the present invention can be used in vaccines that help protect vaccinated subjects (e.g., humans, companion animals, or livestock) from influenza A virus infection, such as helping to prevent influenza A virus infection. In a specific embodiment, the immunogenic compositions and vaccines of the present invention comprise one or more NAs that are derived from influenza A virus and that do not comprise influenza virus hemagglutinin (HA) or its antigenic fragments, nor nucleotide sequences encoding influenza A virus HA or its antigenic fragments.

[0017] In certain embodiments, vectors and / or nucleic acid constructs encoding one or more human influenza A virus NA antigens are provided. In other embodiments, the vectors and / or nucleic acid constructs encode one or more canine influenza virus NA antigens. In yet other embodiments, the vectors and / or nucleic acid constructs encode one or more equine influenza virus NA antigens. In yet other embodiments, the vectors and / or nucleic acid constructs encode one or more avian influenza virus NA antigens. In yet other embodiments, the vectors and / or nucleic acid constructs encode one or more bovine influenza virus NA antigens. In specific embodiments, the vectors and / or nucleic acid constructs encode two to four influenza virus NA antigens.

[0018] In a specific embodiment, the vector is an alphavirus RNA replicon particle that encodes one or more antigens derived from influenza A virus. In a specific embodiment, the alphavirus RNA replicon particle encodes one or more influenza A virus NA. In a related embodiment, the alphavirus RNA replicon particle encodes one or more antigenic fragments of one or more influenza A virus NA. The present invention also includes other vectors and / or nucleic acid constructs that encode one or more antigens derived from swine influenza A virus (IAV-S). In a specific embodiment, the vector and / or nucleic acid construct may also encode one or more IAV-S neuraminidase antigens (NA). In a related embodiment, the vector and / or nucleic acid construct may encode one or more IAV-S antigenic fragments of one or more NA.

[0019] In an important aspect of the present invention, vectors and / or nucleic acid constructs are provided that encode one or more swine influenza A virus (IAV-S) neuraminidase (NA) antigens. Such vectors and / or nucleic acid constructs can be used in immunogenic compositions comprising these vectors. The immunogenic compositions of the present invention can be used in vaccines that help protect vaccinated pig subjects (e.g., sows and / or piglets) from IAV-S infection, for example, helping to prevent swine influenza virus infection. In a specific embodiment, the immunogenic composition and vaccine comprise one or more NAs that are derived from the IAV-S of the present invention, which neither comprise the IAV-S HA or its antigenic fragments nor comprise nucleotide sequences encoding the IAV-S HA or its antigenic fragments. The present invention also provides combination vaccines for stimulating protective immunity against IAV-S and other diseases (e.g., other swine infectious diseases). Methods for preparing and using the immunogenic compositions and vaccines of the present invention are also provided.

[0020] In a more specific embodiment, the vector is an alphavirus RNA replicon particle that encodes one or more antigens derived from IAV-S. In a specific embodiment, the alphavirus RNA replicon particle encodes one or more IAV-S NAs. In a related embodiment, the alphavirus RNA replicon particle encodes one or more antigenic fragments of one or more IAV-S NAs. In a specific embodiment, the alphavirus RNA replicon particle encodes one or more NAs derived from the IAV-S of the present invention, which neither comprises an IAV-S HA or an antigenic fragment thereof, nor comprises a nucleotide sequence encoding an IAV-S HA or an antigenic fragment thereof.

[0021] In certain embodiments, IAV-S NA is derived from the N1-classical phylogenetic cluster. In other embodiments, the alphavirus RNA replicon particles encode antigenic fragments of NA derived from the N1-classical phylogenetic cluster. In still other embodiments, the IAV-S NA is derived from the N2-1998 phylogenetic cluster. In still other embodiments, the alphavirus RNA replicon particles encode antigenic fragments of NA derived from the N2-1998 phylogenetic cluster. In still other embodiments, the IAV-S NA is derived from the N1-pandemic phylogenetic cluster. In still other embodiments, the alphavirus RNA replicon particles encode antigenic fragments of NA derived from the N1-pandemic phylogenetic cluster. In still other embodiments, the IAV-S NA is derived from the N2-2002 phylogenetic cluster. In still other embodiments, the alphavirus RNA replicon particles encode antigenic fragments of NA derived from the N2-2002 phylogenetic cluster.

[0022] In a similar embodiment, the IAV-S NA is derived from- and / or the alphavirus RNA replicon particles encode NA (or an antigenic fragment thereof) from the N1-pandemic (EU) lineage. In a similar embodiment, the IAV-S NA is derived from- and / or the alphavirus RNA replicon particles encode NA (or an antigenic fragment thereof) from the N1-Eurasian avian lineage.

[0023] In a similar embodiment, IAV-S NA is derived from-and / or alphavirus RNA replicon particles encode NA (or antigenic fragments thereof) from the N2-Ghent / 1984 lineage. In another similar embodiment, IAV-S NA is derived from-and / or alphavirus RNA replicon particles encode NA (or antigenic fragments thereof) from the N2-Italy / 2003 lineage. In yet another similar embodiment, IAV-S NA is derived from-and / or alphavirus RNA replicon particles encode NA (or antigenic fragments thereof) from the N2-Scotland / 1994 lineage. In certain embodiments of this type, IAV-S NA is derived from-and / or alphavirus RNA replicon particles encode NA (or antigenic fragments thereof) from the N2-Scotland / 1994 lineage (branch 1). In other embodiments of this type, IAV-S NA is derived from-and / or alphavirus RNA replicon particles encode NA (or antigenic fragments thereof) from the N2-Scotland / 1994 lineage (branch 2). In other embodiments of this type, the IAV-S NA is derived from - and / or the alphavirus RNA replicon particles encode the NA (or antigenic fragment thereof) from A / swine / Italy / 4675 / 2003-like N2. In other embodiments of this type, the IAV-S NA is derived from - and / or the alphavirus RNA replicon particles encode the NA (or antigenic fragment thereof) from human seasonal-like N2.

[0024] In a specific embodiment, the IAV-S NA derived from the N1-classical phylogenetic cluster comprises an amino acid sequence having 95% identity, 97% identity, 98% identity or higher identity to the amino acid sequence set forth in SEQ ID NO: 2. In a more specific embodiment of this type, the NA comprises the amino acid sequence set forth in SEQ ID NO: 2. In an even more specific embodiment of this type, the NA is encoded by the nucleotide sequence set forth in SEQ ID NO: 1. In other embodiments, the IAV-S NA derived from the N1-pandemic phylogenetic cluster comprises an amino acid sequence having 95% identity, 97% identity, 98% identity or higher identity to the amino acid sequence set forth in SEQ ID NO: 4. In a more specific embodiment of this type, the NA comprises the amino acid sequence set forth in SEQ ID NO: 4. In an even more specific embodiment of this type, the NA is encoded by the nucleotide sequence set forth in SEQ ID NO: 3. In yet other embodiments, the IAV-S NA derived from the N2-1998 phylogenetic cluster comprises an amino acid sequence having 92% identity, 94% identity, 97% identity or higher identity to the amino acid sequence set forth in SEQ ID NO: 6. In a more specific embodiment of this type, the NA comprises the amino acid sequence set forth in SEQ ID NO: 6. In an even more specific embodiment of this type, the NA is encoded by the nucleotide sequence set forth in SEQ ID NO: 5. In yet other embodiments, the IAV-S NA derived from the N2-2002 phylogenetic cluster comprises an amino acid sequence having 92% identity, 94% identity, 97% identity or greater identity to the amino acid sequence set forth in SEQ ID NO: 8. In an even more specific embodiment of this type, the NA comprises the amino acid sequence set forth in SEQ ID NO: 8. In an even more specific embodiment of this type, the NA is encoded by the nucleotide sequence set forth in SEQ ID NO: 7.

[0025] In a specific embodiment, the IAV-S NA derived from the N1-pandemic (EU) lineage comprises an amino acid sequence having 90% identity, 92% identity, 95% identity or higher identity to the amino acid sequence set forth in SEQ ID NO: 12. In a more specific embodiment of this type, the NA comprises the amino acid sequence set forth in SEQ ID NO: 12. In an even more specific embodiment of this type, the NA is encoded by the nucleotide sequence set forth in SEQ ID NO: 12. In a related embodiment of this type, the NA is encoded by the nucleotide sequence set forth in SEQ ID NO: 23. In other embodiments, the IAV-S NA derived from the N1-Eurasian avian lineage comprises an amino acid sequence having 85% identity, 90% identity, 95% identity or higher identity to the amino acid sequence set forth in SEQ ID NO: 14. In a more specific embodiment of this type, the NA comprises the amino acid sequence set forth in SEQ ID NO: 14. In an even more specific embodiment of this type, the NA is encoded by the nucleotide sequence set forth in SEQ ID NO: 13. In yet other embodiments, the IAV-S NA derived from the N2-Ghent / 1984 lineage comprises an amino acid sequence having 90% identity, 92% identity, 95% identity or higher identity to the amino acid sequence set forth in SEQ ID NO: 16. In a more specific embodiment of this type, the NA comprises the amino acid sequence set forth in SEQ ID NO: 16. In an even more specific embodiment of this type, the NA is encoded by the nucleotide sequence set forth in SEQ ID NO: 15. In a related embodiment of this type, the NA is encoded by the nucleotide sequence set forth in SEQ ID NO: 24. In yet other embodiments, the IAV-S NA derived from the N2-Italy / 2003 lineage comprises an amino acid sequence having 90% identity, 92% identity, 95% identity or higher identity to the amino acid sequence set forth in SEQ ID NO: 18. In a more specific embodiment of this type, the NA comprises the amino acid sequence set forth in SEQ ID NO: 18. In an even more specific embodiment of this type, the NA is encoded by the nucleotide sequence set forth in SEQ ID NO: 17. In a related embodiment of this type, the NA is encoded by the nucleotide sequence set forth in SEQ ID NO: 25. In other embodiments, the IAV-S NA derived from the N2-Scotland / 1994 (clade 1) lineage comprises an amino acid sequence having 90% identity, 92% identity, 95% identity or higher identity to the amino acid sequence set forth in SEQ ID NO: 20. In a more specific embodiment of this type, the NA comprises the amino acid sequence set forth in SEQ ID NO: 20. In an even more specific embodiment of this type, the NA is encoded by the nucleotide sequence set forth in SEQ ID NO: 19.In related embodiments of this type, the NA is encoded by the nucleotide sequence set forth in SEQ ID NO: 26. In yet other embodiments, the IAV-S NA derived from the N2-Scotland / 1994 (clade 2) lineage comprises an amino acid sequence having 90% identity, 92% identity, 95% identity or greater identity to the amino acid sequence set forth in SEQ ID NO: 22. In more specific embodiments of this type, the NA comprises the amino acid sequence set forth in SEQ ID NO: 22. In even more specific embodiments of this type, the NA is encoded by the nucleotide sequence set forth in SEQ ID NO: 21. In related embodiments of this type, the NA is encoded by the nucleotide sequence set forth in SEQ ID NO: 27.

[0026] In another more specific embodiment, the alphavirus RNA replicon particles are Venezuelan equine encephalitis (VEE) alphavirus RNA replicon particles. In another more specific embodiment, the VEE alphavirus RNA replicon particles are TC-83VEE alphavirus RNA replicon particles. In other embodiments, the alphavirus RNA replicon particles are Sindbis (SIN) alphavirus RNA replicon particles. In other other embodiments, the alphavirus RNA replicon particles are Semliki Forest Virus (SFV) alphavirus RNA replicon particles. In an alternative embodiment, the naked DNA vector comprises a nucleic acid construct encoding one or more antigens derived from a porcine pathogen. In a specific embodiment of this type, the naked DNA vector comprises a nucleic acid construct encoding NA or an antigenic fragment thereof derived from IAV-S. In other embodiments, the naked RNA vector comprises a nucleic acid construct encoding one or more antigens derived from a porcine pathogen. In a specific embodiment of this type, the naked RNA vector comprises a nucleic acid construct encoding NA or an antigenic fragment thereof derived from IAV-S.

[0027] The present invention provides alphavirus RNA replicon particles encoding two or more IAV-S antigens or antigenic fragments thereof. In a specific embodiment, the alphavirus RNA replicon particles encode one or more NAs, wherein the NAs are derived from the IAV-S of the present invention, and neither contain IAV-S HA or antigenic fragments thereof, nor contain nucleotide sequences encoding IAV-S HA or antigenic fragments thereof.

[0028] In a specific embodiment, the alphavirus RNA replicon particles encode two to four or more NA antigens or antigenic fragments thereof derived from IAV-S. In a related embodiment, the alphavirus RNA replicon particles encode two to four or more NA antigens or antigenic fragments thereof derived from different IAV-S phylogenetic clusters. In certain embodiments, the alphavirus RNA replicon particles encode NA or antigenic fragments thereof derived from the N1-classical phylogenetic cluster and NA or antigenic fragments thereof derived from the N2-2002 phylogenetic cluster. In other embodiments, the alphavirus RNA replicon particles encode NA or antigenic fragments thereof derived from the N1-classical phylogenetic cluster and NA or antigenic fragments thereof derived from the N2-1998 phylogenetic cluster. In yet other embodiments, the alphavirus RNA replicon particles encode NA or antigenic fragments thereof derived from the N1-classical phylogenetic cluster and NA or antigenic fragments thereof derived from the N1-pandemic phylogenetic cluster.

[0029] In certain embodiments, the alphavirus RNA replicon particles encode NA or antigenic fragments thereof derived from the N1-pandemic (EU) lineage and NA or antigenic fragments thereof derived from the N1-Eurasian avian lineage. In other embodiments, the alphavirus RNA replicon particles encode NA or antigenic fragments thereof derived from the N2-Ghent / 1984 lineage and NA or antigenic fragments thereof derived from the N2-Italian / 2003 lineage. In still other embodiments, the alphavirus RNA replicon particles encode NA or antigenic fragments thereof derived from the N2-Ghent / 1984 lineage and NA or antigenic fragments thereof derived from the N2-Scotland / 1994 (branch 1) lineage. In still other embodiments, the alphavirus RNA replicon particles encode NA or antigenic fragments thereof derived from the N2-Ghent / 1984 lineage and NA or antigenic fragments thereof derived from the N2-Scotland / 1994 (branch 2) lineage. In yet other embodiments, the alphavirus RNA replicon particles encode NA or antigenic fragments thereof derived from the N2-Italian / 2003 lineage and NA or antigenic fragments thereof derived from the N2-Scotland / 1994 (branch 1) lineage. In yet other embodiments, the alphavirus RNA replicon particles encode NA or antigenic fragments thereof derived from the N2-Italian / 2003 lineage and NA or antigenic fragments thereof derived from the N2-Scotland / 1994 (branch 2) lineage. In yet other embodiments, NA or antigenic fragments thereof derived from one of the European N1 lineages are encoded in the alphavirus RNA replicon particles together with NA or antigenic fragments thereof derived from one of the European N2 lineages. Similarly, the present invention includes alphavirus RNA replicon particles encoding three, four or more NAs, each NA being derived from a different European lineage. In addition, the present invention includes alphavirus RNA replicon particles encoding two, three, four or more NAs, each NA being derived from a different European lineage and / or phylogenetic cluster.

[0030] Therefore, the present invention also provides alphavirus RNA replicon particles, which encode three or four IAV-S antigens or antigenic fragments thereof. In a specific embodiment, the immunogenic composition comprises alphavirus RNA replicon particles, which encode three or four NA antigens or antigenic fragments thereof derived from IAV-S. In a related embodiment, the immunogenic composition comprises alphavirus RNA replicon particles, which encode three or four NA antigens or antigenic fragments thereof derived from different IAV-S phylogenetic clusters. In certain embodiments, the alphavirus RNA replicon particles encode NA or antigenic fragments thereof derived from the N1-classical phylogenetic cluster, NA or antigenic fragments thereof derived from the N2-2002 phylogenetic cluster, and NA or antigenic fragments thereof derived from the N2-1998 phylogenetic cluster. In other embodiments, the alphavirus RNA replicon particles encode NA or antigenic fragments thereof derived from the N1-classical phylogenetic cluster, NA or antigenic fragments thereof derived from the N2-2002 phylogenetic cluster, and NA or antigenic fragments thereof derived from the N1-pandemic phylogenetic cluster. In other embodiments, the alphavirus RNA replicon particles encode NA or antigenic fragments thereof derived from the N1-classical phylogenetic cluster, NA or antigenic fragments thereof derived from the N2-1998 phylogenetic cluster, and NA or antigenic fragments thereof derived from the N1-pandemic phylogenetic cluster. In other embodiments, the alphavirus RNA replicon particles encode NA or antigenic fragments thereof derived from the N2-2002 phylogenetic cluster, NA or antigenic fragments thereof derived from the N2-1998 phylogenetic cluster, and NA or antigenic fragments thereof derived from the N1-pandemic phylogenetic cluster.

[0031] In a specific embodiment, the alphavirus RNA replicon particles encode four or more IAV-S NA antigens or antigenic fragments thereof. In a more specific embodiment, the alphavirus RNA replicon particles encode four or more NA antigens or antigenic fragments thereof derived from different IAV-S phylogenetic clusters. In an even more specific embodiment, the alphavirus RNA replicon particles encode NA or antigenic fragments thereof derived from the N2-2002 phylogenetic cluster, NA or antigenic fragments thereof derived from the N2-1998 phylogenetic cluster, NA or antigenic fragments thereof derived from the N1-pandemic phylogenetic cluster, and NA or antigenic fragments thereof derived from the N1-classical phylogenetic cluster.

[0032] In similar embodiments as described above, the alphavirus RNA replicon particles encode three, four or more IAV-S NA antigens or antigenic fragments thereof derived from the IAV-S N1-pandemic (EU) lineage, the N1-Eurasian avian lineage, the NA lineage, the N2-Ghent / 1984 lineage, the N2-Italian / 2003 lineage, the N2-Scotland / 1994 (branch 1) lineage and / or the N2-Scotland / 1994 (branch 2) lineage.

[0033] As described above, all alphavirus RNA replicon particles of the invention may be components of an immunogenic composition and / or vaccine. Thus, an immunogenic composition and / or vaccine of the invention may comprise one or more alphavirus RNA replicon particles of the invention. In certain embodiments, an immunogenic composition and / or vaccine comprises only one set of identical alphavirus RNA replicon particles, which may encode one or more NAs derived from one or more phylogenetic clusters and / or one or more lineages, as described in detail above.

[0034] In a more specific embodiment of this type, the immunogenic composition and / or vaccine comprises RNA replicon particles encoding both NA (or antigenic fragments thereof) derived from the N1-phylogenetic cluster and NA (or antigenic fragments thereof) derived from the N2-phylogenetic cluster. In particular, the immunogenic composition and / or vaccine comprises an RNA replicon wherein the first NA belongs to an N1-phylogenetic cluster selected from the N1-classical and N1-pandemic phylogenetic clusters and the second NA belongs to an N2-phylogenetic cluster selected from the N2-1998 and N2-2002 phylogenetic clusters.

[0035] In a more specific embodiment of this type, the immunogenic composition and / or vaccine comprises an RNA replicon wherein the first NA belongs to an N1-lineage selected from the N1-pandemic (EU) and N1-Eurasian avian lineages and the second NA belongs to an N2-phylogenetic lineage selected from the N2-Ghent / 1984, N2-Italy / 2003, N2-Scotland 1994 (branch 1) lineages and N2-Scotland 1994 (branch 2) lineages.

[0036] The present invention also provides immunogenic compositions and / or vaccines comprising two or more sets of such alphavirus RNA replicon particles. In a specific embodiment of this type, one set of alphavirus RNA replicon particles encodes one or more NAs derived from one phylogenetic cluster and / or lineage, while the other set of alphavirus RNA replicon particles encodes one or more NAs derived from another phylogenetic cluster and / or lineage.

[0037] In a specific embodiment of this type, a first group of alphavirus RNA replicon particles encodes one or more NA antigens or antigenic fragments thereof derived from an N1-phylogenetic cluster and / or lineage, and a second group of alphavirus RNA replicon particles encodes one or more NA antigens or antigenic fragments thereof derived from an N2-phylogenetic cluster and / or lineage. In particular, in the first group, the NA antigens (or fragments thereof) belong to an N1-phylogenetic cluster selected from the N1-classical and N1-pandemic phylogenetic clusters, and in the second group, the NA antigens (or antigenic fragments thereof) belong to an N2-phylogenetic cluster selected from the N2-1998 and N2-2002 phylogenetic clusters.

[0038] In similar, parallel embodiments, in a first group, the NA antigen (or a fragment thereof) belongs to an N1-phylogenetic lineage selected from the N1-pandemic (EU) and N1-Eurasian avian lineages, and in a second group, the NA antigen (or an antigenic fragment thereof) belongs to an N2-lineage selected from the N2-Ghent / 1984, N2-Italian / 2003, N2-Scottish 1994 (branch 1) lineages and N2-Scottish 1994 (branch 2) lineages.

[0039] In yet other embodiments, the immunogenic composition and / or vaccine comprises a set of alphavirus RNA replicon particles encoding a first antigen, another set of alphavirus RNA replicon particles encoding a second antigen, and a third set of alphavirus RNA replicon particles encoding a third antigen. More specifically, in the immunogenic composition and / or vaccine, the antigen is a NA antigen of a phylogenetic cluster selected from the group consisting of the N1-classical, N1-pandemic, N2-1998, and N2-2002 phylogenetic clusters, or it is a NA antigen of a lineage selected from the group consisting of the N1-pandemic (EU), N1-Eurasian avian, N2-Ghent / 1984, N2-Italian / 2003, N2-Scotland 1994 (branch 1) lineage, and N2-Scotland 1994 (branch 2) lineage.

[0040] In a specific embodiment of this type, a first group of alphavirus RNA replicon particles encodes NA or an antigenic fragment thereof derived from the N1 classical phylogenetic cluster; a second group of alphavirus RNA replicon particles encodes NA or an antigenic fragment thereof derived from the N2-2002 phylogenetic cluster; and a third group of alphavirus RNA replicon particles encodes NA or an antigenic fragment thereof derived from the N2-1998 phylogenetic cluster.

[0041] In yet other embodiments, the immunogenic composition and / or vaccine comprises one set of alphavirus RNA replicon particles encoding a first antigen, another set of alphavirus RNA replicon particles encoding a second antigen, a third set of alphavirus RNA replicon particles encoding a third antigen, and a fourth set of alphavirus RNA replicon particles encoding a fourth antigen.

[0042] More specifically, in the immunogenic composition and / or vaccine, the antigen is a NA antigen of a phylogenetic cluster selected from the group consisting of the N1-classical phylogenetic cluster, the N1-pandemic phylogenetic cluster, the N2-1998 phylogenetic cluster and the N2-2002 phylogenetic cluster, or it is a NA antigen of a lineage selected from the group consisting of the N1-pandemic (EU) lineage, the N1-Eurasian avian lineage, the N2-Ghent / 1984 lineage, the N2-Italian / 2003 lineage, the N2-Scottish 1994 (branch 1) lineage and the N2-Scottish 1994 (branch 2) lineage.

[0043] In a specific embodiment of this type, a first group of alphavirus RNA replicon particles encodes NA or an antigenic fragment thereof derived from the N1-classical phylogenetic cluster; a second group of alphavirus RNA replicon particles encodes NA or an antigenic fragment thereof derived from the N2-2002 phylogenetic cluster; a third group of alphavirus RNA replicon particles encodes NA or an antigenic fragment thereof derived from the N2-1998 phylogenetic cluster; and a fourth group of alphavirus RNA replicon particles encodes NA or an antigenic fragment thereof derived from the N1-pandemic phylogenetic cluster.

[0044] Thus, in one aspect of the invention, the immunogenic composition / vaccine comprises a plurality of groups (e.g., 2-10 groups) of alphavirus RNA replicon particles. In a specific embodiment of this type, one or more groups comprise alphavirus RNA replicon particles encoding one or more IAV-S NAs derived from one or more phylogenetic clusters (or antigenic fragments thereof) or lineages (or antigenic fragments thereof). In a specific embodiment of this type, the immunogenic composition comprises one or more groups of alphavirus RNA replicon particles encoding one or more IAV-S NAs derived from one or more phylogenetic clusters (or antigenic fragments thereof) or lineages (or antigenic fragments thereof), in combination with one or more groups of alphavirus RNA replicon particles encoding one or more non-IAV-S antigens or antigenic fragments thereof. In an even more specific embodiment, one or more groups of alphavirus RNA replicon particles encode one or more IAV-S NAs derived from one or more phylogenetic clusters (or antigenic fragments thereof) or lineages (or antigenic fragments thereof) and encode one or more non-IAV-S antigens or antigenic fragments thereof. In a specific embodiment of this type, the alphavirus RNA replicon particle encodes NA or an antigenic fragment thereof derived from the N1-classical phylogenetic cluster and / or NA or an antigenic fragment thereof derived from the N2-2002 phylogenetic cluster, and one to three non-IAV-S antigens or antigenic fragments thereof.

[0045] In certain embodiments, the non-IAV-S antigen is derived from porcine reproductive and respiratory syndrome virus (PRRS). In other embodiments, the non-IAV-S antigen is derived from porcine circovirus (PCV). In other embodiments, the non-IAV-S antigen is derived from transmissible gastroenteritis virus (TGE). In still other embodiments, the non-IAV-S antigen is derived from pseudorabies virus (PPRV). In still other embodiments, the non-IAV-S antigen is derived from porcine parvovirus (PPV). In still other embodiments, the non-IAV-S antigen is derived from porcine rotavirus (PRV). In still other embodiments, the non-IAV-S antigen is derived from porcine epidemic diarrhea virus (PED). In still other embodiments, one or more non-IAV-S antigens are derived from one or more serotypes of Pasteurella multocida. In still other embodiments, one or more non-IAV-S antigens are derived from one or more serotypes of Salmonella ssp. In yet other embodiments, one or more non-IAV-S antigens are derived from one or more serotypes of Escherichia coli. In yet other embodiments, one or more non-IAV-S antigens are derived from one or more serotypes of Haemophilus parasuis. In yet other embodiments, non-IAV-S antigens are derived from Lawsonia intracellularis. In yet other embodiments, non-IAV-S antigens are derived from Mycoplasma ssp (e.g., Mycoplasma hyopneumoniae). In yet other embodiments, non-IAV-S antigens are derived from Bordetellabronchiseptica. In yet other embodiments, non-IAV-S antigens are derived from Erysipelas ssp. In yet other embodiments, non-IAV-S antigens are derived from Campylobacter ssp. In yet other embodiments, the non-IAV-S antigen is derived from Actinobacillus pleuropneumoniae. In yet other embodiments, the non-IAV-S antigen is derived from Clostridium perfringens. In yet other embodiments, the non-IAV-S antigen is derived from Clostridium difficile.

[0046] In a more specific embodiment, the alphavirus RNA replicon particle is a Venezuelan equine encephalitis (VEE) alphavirus RNA replicon particle. In another more specific embodiment, the VEE alphavirus RNA replicon particle is a TC-83 VEE alphavirus RNA replicon particle.

[0047] The present invention also provides a combined immunogenic composition and / or vaccine (multivalent vaccine) comprising an alphavirus RNA replicon particle encoding one or more NA or antigenic fragments thereof derived from IAV-S, as described above, and further comprising one or more modified live / attenuated or inactivated porcine pathogens. In a specific embodiment, the immunogenic composition further comprises one or more modified live / attenuated and / or inactivated PRRS viruses. In other embodiments, the immunogenic composition further comprises one or more modified live / attenuated and / or inactivated PCVs. In yet other embodiments, the immunogenic composition further comprises one or more modified live / attenuated and / or inactivated TGEs. In yet other embodiments, the immunogenic composition further comprises one or more modified live / attenuated and / or inactivated PPRVs. In yet other embodiments, the immunogenic composition further comprises one or more modified live / attenuated and / or inactivated PPVs. In yet other embodiments, the immunogenic composition further comprises one or more modified live / attenuated and / or inactivated PRVs. In yet other embodiments, the immunogenic composition further comprises one or more modified live / attenuated and / or inactivated PRVs. In yet other embodiments, the immunogenic composition further comprises one or more modified live / attenuated and / or inactivated PEDs. In yet other embodiments, the immunogenic composition further comprises one or more modified live / attenuated and / or inactivated serotypes of Pasteurella multocida. In yet other embodiments, the immunogenic composition further comprises one or more modified live / attenuated and / or inactivated serotypes of Salmonella species. In yet other embodiments, the immunogenic composition further comprises one or more modified live / attenuated and / or inactivated serotypes of Escherichia coli. In yet other embodiments, the immunogenic composition further comprises one or more modified live / attenuated and / or inactivated Haemophilus parasuis. In yet other embodiments, the immunogenic composition further comprises one or more modified live / attenuated and / or inactivated Lawsonia intracellularis. In yet other embodiments, the immunogenic composition further comprises one or more modified live / attenuated and / or inactivated Mycoplasma species (e.g., Mycoplasma hyopneumoniae). In yet other embodiments, the immunogenic composition further comprises one or more modified live / attenuated and / or inactivated Bordetella bronchiseptica. In yet other embodiments, the immunogenic composition further comprises one or more modified live / attenuated and / or inactivated Erysipelothrix species. In yet other embodiments, the immunogenic composition further comprises one or more modified live / attenuated and / or inactivated Campylobacter species. In yet other embodiments, the immunogenic composition further comprises one or more modified live / attenuated and / or inactivated Actinobacillus pleuropneumoniae. In yet other embodiments, the immunogenic composition further comprises one or more modified live / attenuated and / or inactivated Clostridium perfringens. In yet other embodiments, the immunogenic composition further comprises one or more modified live / attenuated and / or inactivated Clostridium difficile.

[0048] In a specific embodiment, the nucleic acid construct of the present invention encodes one or more NA or antigenic fragments thereof derived from the IAV-S phylogenetic cluster. Therefore, although the alpha virus RNA replicon particles are specifically exemplified below, it should be understood that the present invention also includes other vectors and / or nucleic acid constructs.

[0049] Therefore, in certain embodiments, the nucleic acid construct encodes an IAV-SNA derived from the N1-classical phylogenetic cluster. In other embodiments, the nucleic acid construct encodes an antigenic fragment of the NA derived from the N1-classical phylogenetic cluster. In other embodiments, the IAV-S NA is derived from the N2-1998 phylogenetic cluster. In yet other embodiments, the alphavirus RNA replicon particle encodes an antigenic fragment of the NA derived from the N2-1998 phylogenetic cluster. In yet other embodiments, the IAV-S NA is derived from the N1-pandemic phylogenetic cluster. In yet other embodiments, the alphavirus RNA replicon particle encodes an antigenic fragment of the NA derived from the N1-pandemic phylogenetic cluster. In yet other embodiments, the IAV-S NA is derived from the N2-2002 phylogenetic cluster. In yet other embodiments, the nucleic acid construct encodes an antigenic fragment of the NA derived from the N2-2002 phylogenetic cluster.

[0050] In a similar embodiment, IAV-S NA derives from NA from N1-pandemic (EU) pedigree. In a similar embodiment, IAV-S NA derives from NA from N1-Eurasian poultry pedigree. In a similar embodiment, IAV-S NA derives from NA from N2-Ghent / 1984 pedigree. In another similar embodiment, IAV-S NA derives from N2-Italy / 2003 pedigree. In another similar embodiment, IAV-S NA derives from N2-Scotland / 1994 pedigree. In some embodiments of this type, IAV-S NA derives from N2-Scotland / 1994 pedigree (branch 1). In other embodiments of this type, IAV-S NA derives from N2-Scotland / 1994 pedigree (branch 2).

[0051] In a specific embodiment, the IAV-S NA derived from the N1-classical phylogenetic cluster comprises an amino acid sequence having 95% identity, 97% identity, 98% identity or higher identity to the amino acid sequence set forth in SEQ ID NO: 2. In a more specific embodiment of this type, the NA comprises the amino acid sequence set forth in SEQ ID NO: 2. In other embodiments, the IAV-S NA derived from the N1-pandemic phylogenetic cluster comprises an amino acid sequence having 95% identity, 97% identity, 98% identity or higher identity to the amino acid sequence set forth in SEQ ID NO: 4. In a more specific embodiment of this type, the NA comprises the amino acid sequence set forth in SEQ ID NO: 4. In still other embodiments, the IAV-S NA derived from the N2-1998 phylogenetic cluster comprises an amino acid sequence having 92% identity, 94% identity, 97% identity or higher identity to the amino acid sequence set forth in SEQ ID NO: 6. In a more specific embodiment of this type, the NA comprises the amino acid sequence set forth in SEQ ID NO: 6. In yet other embodiments, the IAV-SNA derived from the N2-2002 phylogenetic cluster comprises an amino acid sequence having 92% identity, 94% identity, 97% identity or higher identity to the amino acid sequence shown in SEQ ID NO: 8. In more specific embodiments of this type, the NA comprises the amino acid sequence shown in SEQ ID NO: 8.

[0052] In a specific embodiment, the IAV-S NA derived from the N1-pandemic (EU) lineage comprises an amino acid sequence having 90% identity, 92% identity, 95% identity or higher identity to the amino acid sequence set forth in SEQ ID NO: 12. In a more specific embodiment of this type, the NA comprises the amino acid sequence set forth in SEQ ID NO: 12. In other embodiments, the IAV-S NA derived from the N1-Eurasian avian lineage comprises an amino acid sequence having 85% identity, 90% identity, 95% identity or higher identity to the amino acid sequence set forth in SEQ ID NO: 14. In a more specific embodiment of this type, the NA comprises the amino acid sequence set forth in SEQ ID NO: 14. In still other embodiments, the IAV-S NA derived from the N2-Ghent / 1984 lineage comprises an amino acid sequence having 90% identity, 92% identity, 95% identity or higher identity to the amino acid sequence set forth in SEQ ID NO: 16. In a more specific embodiment of this type, the NA comprises the amino acid sequence set forth in SEQ ID NO: 16. In yet other embodiments, the IAV-S NA derived from the N2-Italian / 2003 lineage comprises an amino acid sequence having 90% identity, 92% identity, 95% identity or higher identity to the amino acid sequence set forth in SEQ ID NO: 18. In more specific embodiments of this type, the NA comprises the amino acid sequence set forth in SEQ ID NO: 18. In other embodiments, the IAV-S NA derived from the N2-Scotland / 1994 (branch 1) lineage comprises an amino acid sequence having 90% identity, 92% identity, 95% identity or higher identity to the amino acid sequence set forth in SEQ ID NO: 20. In more specific embodiments of this type, the NA comprises the amino acid sequence set forth in SEQ ID NO: 20. In yet other embodiments, the IAV-S NA derived from the N2-Scotland / 1994 (branch 2) lineage comprises an amino acid sequence having 90% identity, 92% identity, 95% identity or higher identity to the amino acid sequence set forth in SEQ ID NO: 22. In a more specific embodiment of this type, the NA comprises the amino acid sequence shown in SEQ ID NO:22.

[0053] The present invention provides a nucleic acid construct encoding two or more IAV-S antigens or antigenic fragments thereof. In a specific embodiment, the nucleic acid construct encodes two to four or more NA antigens or antigenic fragments thereof derived from IAV-S. In a related embodiment, the nucleic acid construct encodes two to four or more NA antigens or antigenic fragments thereof derived from different IAV-S system occurrence clusters. In certain embodiments, the nucleic acid construct encodes NA or antigenic fragments thereof derived from the N1-classical system occurrence cluster and NA or antigenic fragments thereof derived from the N2-2002 system occurrence cluster. In an even more specific embodiment, the nucleic acid construct encodes NA or antigenic fragments thereof derived from the N2-2002 system occurrence cluster, NA or antigenic fragments thereof derived from the N2-1998 system occurrence cluster, NA or antigenic fragments thereof derived from the N1-pandemic system occurrence cluster and NA or antigenic fragments thereof derived from the N1-classical system occurrence cluster.

[0054] In certain embodiments, the nucleic acid construct encodes NA or its antigenic fragment derived from the N1-pandemic (EU) pedigree and NA or its antigenic fragment derived from the N1-Eurasian avian pedigree. In other embodiments, the nucleic acid construct encodes NA or its antigenic fragment derived from the N2-Ghent / 1984 pedigree and NA or its antigenic fragment derived from the N2-Italy / 2003 pedigree. In other embodiments, the nucleic acid construct encodes NA or its antigenic fragment derived from the N2-Ghent / 1984 pedigree and NA or its antigenic fragment derived from the N2-Scotland / 1994 (branch 1) pedigree. In other embodiments, the nucleic acid construct encodes NA or its antigenic fragment derived from the N2-Ghent / 1984 pedigree and NA or its antigenic fragment derived from the N2-Scotland / 1994 (branch 2) pedigree. In other embodiments, the nucleic acid construct encodes NA or its antigenic fragment derived from the N2-Italy / 2003 pedigree and NA or its antigenic fragment derived from the N2-Scotland / 1994 (branch 1) pedigree. In yet other embodiments, the nucleic acid construct encodes NA or an antigenic fragment thereof derived from the N2-Italian / 2003 pedigree and NA or an antigenic fragment thereof derived from the N2-Scotland / 1994 (branch 2) pedigree. In yet other embodiments, NA or an antigenic fragment thereof derived from one of the European N1 pedigrees is encoded together with NA or an antigenic fragment thereof derived from one of the European N2 pedigrees in the same nucleic acid construct. Similarly, the present invention includes nucleic acid constructs encoding three, four or more NAs, each NA being derived from a different European pedigree. In addition, the present invention includes nucleic acid constructs encoding two, three, four or more NAs, each NA being derived from a different European pedigree and / or phylogenetic cluster.

[0055] Therefore, the present invention also includes all alphavirus RNA replicon particles of the present invention, naked DNA vectors comprising the nucleic acid constructs of the present invention, naked RNA vectors comprising the nucleic acid constructs of the present invention, nucleic acid constructs of the present invention comprising synthetic messenger RNA and RNA replicons, and all immunogenic compositions and / or vaccines comprising the nucleic acid constructs of the present invention (e.g., synthetic messenger RNA, RNA replicons), alphavirus RNA replicon particles, naked RNA vectors and / or naked DNA vectors.

[0056] The present invention also comprises a vaccine (multivalent vaccine) comprising an immunogenic composition of the present invention. In a specific embodiment, the vaccine is an adjuvant-free vaccine. In other embodiments, the vaccine comprises an adjuvant. In a specific embodiment, the adjuvant is a biodegradable oil. In a specific embodiment of this type, the biodegradable oil is dl-α-tocopheryl acetate (vitamin E acetate). In other embodiments, the adjuvant comprises an oil-in-water emulsion with 2.5%-50% (v / v) mineral oil. In a specific embodiment, the adjuvant comprises an oil-in-water emulsion with 2.5% (v / v) mineral oil. In a related embodiment, the adjuvant comprises an oil-in-water emulsion with 5% (v / v) mineral oil. In other embodiments, the adjuvant comprises an oil-in-water emulsion with 12.5% ​​(v / v) mineral oil. In other other embodiments, the adjuvant comprises an oil-in-water emulsion with 25% (v / v) mineral oil. In yet other embodiments, the adjuvant comprises an oil-in-water emulsion with 50% (v / v) mineral oil. In a more specific embodiment, the adjuvant comprises a mixture of a degradable oil and a mineral oil adjuvant. In a specific embodiment, the degradable oil is dl-α-tocopheryl acetate and the mineral oil is liquid paraffin. In a more specific embodiment, the degradable oil is dl-α-tocopheryl acetate and the mineral oil is light liquid paraffin.

[0057] In certain embodiments, the vaccine helps prevent disease caused by IAV-S. In related embodiments, when the vaccine is used to immunize pigs, antibodies are induced in pig subjects. In certain embodiments, the pig subject is a sow. In related embodiments, the vaccine provides protective maternal antibodies to the offspring of the vaccinated sow. In other embodiments, the pig subject is a piglet. In a specific embodiment of this type, the vaccine is administered to piglets at a minimum age of 3 days. In a specific embodiment, the vaccine is administered as a booster vaccine. In certain embodiments, the vaccine is administered as a single-dose vaccine. In a specific embodiment of this type, the vaccine is administered as a booster vaccine. In yet other embodiments, the vaccine is administered as a multi-dose vaccine. In a specific embodiment of this type, the vaccine is administered as a two-dose vaccine.

[0058] The present invention also provides a method for immunizing a pig (e.g., a sow or a piglet) against a porcine pathogen, comprising administering to the pig an immunologically effective amount of a vaccine or a multivalent vaccine of the present invention. In a specific embodiment, the vaccine is administered by intramuscular injection. In an alternative embodiment, the vaccine is administered by subcutaneous injection. In other embodiments, the vaccine is administered by intravenous injection. In yet other embodiments, the vaccine is administered by intradermal injection. In yet other embodiments, the vaccine is administered by oral administration. In yet other embodiments, the vaccine is administered by intranasal administration.

[0059] Therefore, the vaccine of the present invention and multivalent vaccine can be used as a primary immunization vaccine and / or a booster vaccine. In a specific embodiment, the vaccine of the present invention is used as a single injection vaccine (one dose), and no subsequent administration is required. In certain embodiments, in the case of applying both the primary immunization vaccine and the booster vaccine, the primary immunization vaccine and the booster vaccine can be applied in the same way. In certain embodiments of this type, the primary immunization vaccine and the booster vaccine are both applied by intradermal injection. In other embodiments of this type, the primary immunization vaccine and the booster vaccine are both applied by intramuscular injection. In alternative embodiments, in the case of applying both the primary immunization vaccine and the booster vaccine, the application of the primary immunization vaccine can be carried out by one approach and the booster vaccine can be applied by another approach. In certain embodiments of this type, the primary immunization vaccine can be applied by intradermal injection and the booster vaccine can be applied orally. In the related embodiments of this type, the primary immunization vaccine can be applied by intramuscular injection and the booster vaccine can be applied orally. In other embodiments of this type, the primary immunization vaccine can be applied by intramuscular injection and the booster vaccine can be applied by intradermal injection. In other embodiments of this type, the primary immunization vaccine can be applied by intradermal injection and the booster vaccine can be applied by intramuscular injection. In other embodiments of this type, the primary immunization vaccine can be applied by intradermal injection and the booster vaccine can be applied by intramuscular injection.

[0060] The present invention also provides a method for immunizing a pig (e.g., a sow or a piglet) against IAV-S, comprising administering to the pig an immunologically effective amount of the vaccine of the present invention described above. In a specific embodiment, the vaccine may comprise about 1x10 4 About 1x10 10 RP or more RP, for example. In a more specific embodiment, the vaccine may contain about 1x10 5 About 1x10 9 In even more specific embodiments, the vaccine may comprise about 1 x 10 6 to about x10 8 RP.

[0061] In a specific embodiment, the vaccine of the present invention is administered in a dose of 0.05 mL to 3 mL. In a more specific embodiment, the dose administered is 0.1 mL to 2 mL. In another more specific embodiment, the dose administered is 0.2 mL to 1.5 mL. In an even more specific embodiment, the dose administered is 0.3 mL to 1.0 mL. In another more specific embodiment, the dose administered is 0.4 mL to 0.8 mL.

[0062] These and other aspects of the invention will be better understood with reference to the following drawings and detailed description. BRIEF DESCRIPTION OF THE DRAWINGS

[0063] Figures 1A-1D Serum neuraminidase inhibition (NI) antibody responses were shown to be specific for all four NA strains of the vaccine composition described below in Example 1. Serum samples were collected before the first vaccination (3 weeks of age), before the second vaccination (6 weeks of age), and before challenge (9 weeks of age).

[0064] Figure 2A and 2B Described are administration of the vaccine composition described in Example 1 below and lung lesion scoring of pigs following challenge infection with either (A) H1.γ-N1-classical or (B) H1-δ1-N2-2002A virus.

[0065] Figure 3A and 3B Described are administration of the vaccine composition described in Example 1 below, and viral titers in nasal swab samples of pigs following challenge infection with either (A) H1-γ-N1-classical or (B) H1-δ1-N2-2002A virus.

[0066] Figure 4A and 4B Described are virus titers in bronchoalveolar lavage fluid specimens of pigs following administration of the vaccine composition described in Example 1 below and challenge infection with (A) H1-γ-N1-classical or (B) H1-δ1-N2-2002A virus.

[0067] Figure 5 Serum neuraminidase inhibition (NI) antibody responses specific for the N1-classical strain of the vaccine composition described in Example 2 are described. Serum samples were collected before the first vaccination (3 weeks of age), before the second vaccination (7 weeks of age), and before challenge (10 weeks of age).

[0068] Figure 6 Shown are lung lesion scores of pigs administered the vaccine composition described in Example 2 and challenge infected with H1-γ-N1-classical virus.

[0069] Figure 7 The percentage of macroscopic lung lesions at 5 days after infection with the H1N2 virus is depicted.

[0070] Figure 8 described nasal shedding following infection with the H1N2 virus.

[0071] Fig. 9 Shows that after vaccination, the 2002 Neuraminidase inhibition (NI) titer of vaccine fractions. Note: DPV = days post vaccination DETAILED DESCRIPTION

[0072] The present invention provides vaccines and immunogenic compositions comprising an immunologically effective amount of one or more alphavirus RNA replicon particles, wherein the alphavirus RNA replicon particles encode one or more neuraminidase (NA) from one or more influenza A virus serotypes. In one aspect of the present invention, the vaccine and immunogenic composition contain neither hemagglutinin (HA) or its antigenic fragments nor nucleotide sequences encoding HA or its antigenic fragments. An advantage of influenza A virus vaccines based on multiple NAs and without HA is that NA is less affected by antigenic drift than HA, which enables the corresponding vaccine to contain antigens from fewer influenza isolates. This saves production costs and prolongs the time required to update a specific influenza vaccine. In addition, because the currently commercially available influenza A virus vaccines are based on inactivated influenza viruses, the HA antibody titers produced in animal subjects are much higher than NA antibodies, so the negative effects of maternal antibodies on the immunity of animal subject offspring should be significantly reduced for NA-based vaccines.

[0073] In an important aspect of the invention, vaccines and immunogenic compositions are provided that include an immunologically effective amount of one or more alphavirus RNA replicon particles encoding one or more neuraminidase (NA) from one or more swine influenza A virus (IAV-S) phylogenetic clusters and / or lineages. In one aspect of the invention, vaccines and immunogenic compositions do not include IAV-S hemagglutinin (HA) or antigenic fragments thereof, nor do they include nucleotide sequences encoding IAV-S HA or antigenic fragments thereof.

[0074] As mentioned above, IAV-S based on multiple NA and HA-free can make the corresponding vaccine contain antigens from fewer IAV-S isolates. This saves production costs and extends the time required to update a given IAV-S vaccine. In addition, because the current commercially available IAV-S vaccines are based on inactivated influenza viruses, the HA antibody titers produced in animal subjects are much higher than NA antibodies, so the negative effects of maternal antibodies on piglet immunity should be significantly reduced for vaccines based on neuraminidase.

[0075] In order that the present invention may be more fully understood, the following definitions are provided.

[0076] The singular form of the term is used for ease of description and is not intended to be limiting. Thus, for example, reference to a composition comprising "a polypeptide" includes reference to one or more such polypeptides. Additionally, reference to an "alphavirus RNA replicon particle" includes reference to a plurality of such alphavirus RNA replicon particles unless otherwise specified.

[0077] As used herein, the term "approximately" is used interchangeably with "about" to refer to a value within 50 percent of the stated value, i.e., about 1 x 10 8 The composition of alphavirus RNA replicon particles contains 5x10 7 Up to 1.5x10 8 Alphavirus RNA replicon particles.

[0078] As used herein, unless otherwise indicated, the terms "pig" or "swine" or "porcine" are used interchangeably and include all domesticated pig species.

[0079] As used in this article, "system generation cluster" is a group of influenza virus neuraminidase, which has been grouped together (on the same branch) in a system generation tree or evolutionary tree rooted in similar (homologous) ancestors (see, embodiment 5). For the IAV-S neuraminidase (NA) found in the U.S., there are two main N1 system generation clusters N1-classical and N1-pandemic, and two main N2 system generation clusters N2-1998 and N2-2002. The N1 classic system generation cluster includes the NA combined with the NA of H1N1 classical swine influenza virus. The N1 pandemic system generation cluster includes the NA combined with the NA from the H1N1 pandemic influenza virus. The N2-1998 system generation cluster includes the NA combined with the NA of human H3N2 influenza virus (it jumped into pigs in 1998), and the N2-2002 system generation cluster includes the NA combined with the NA of human H3N2 influenza virus (it jumped into pigs in 2002). [See, Anderson et al., Influenza and other Respiratory Viruses 7 (Suppl. 4): 42-51 (2013)]. Example 5 provides a methodology for determining phylogenetic clusters. For the US IAV-SN phylogenetic clusters of N1-classic, N1-pandemic, N2-1998, and N2-2002, the corresponding representative neuraminidase has the following amino acid sequences, SEQ ID NO: 2, SEQ ID NO: 4, SEQ ID NO: 6, and SEQ ID NO: 8, respectively.

[0080] As used in this article, "pedigree" is a group of influenza virus neuraminidase, which has been grouped together (on the same branch) in a phylogenetic tree rooted in similar (homologous) ancestors (see, Example 6 below). These groupings have been carried out for European neuraminidase, which is similar to the systematic cluster of the United States, but is not identical. As described in Example 6 below, the determination results of pedigree can be obtained using readily available software (i.e., MEGA X). For the EU IAV-SN pedigree of N1- pandemic (EU), N1- Eurasian avian, N2- Ghent / 1984, N2- Italy / 4675 / 2003, N2- Scotland / 1994 branch 1 or N2- Scotland / 1994 branch 2, the corresponding representative neuraminidase has the following amino acid sequence SEQ ID NO: 12, SEQ ID NO: 14, SEQ ID NO: 16, SEQ ID NO: 18, SEQ ID NO: 20 and 22, respectively.

[0081] As used herein, the term "replicon" refers to a modified RNA viral genome lacking one or more elements (e.g., coding sequences for structural proteins) that, if present, would enable the parental virus to be successfully propagated in cell culture or an animal host. In a suitable cellular environment, the replicon will amplify itself and can produce one or more subgenomic RNA species.

[0082] As used herein, the term "alphavirus RNA replicon particle" (abbreviated as "RP") is an alphavirus-derived replicon packaged in viral structural proteins (e.g., capsid and glycoproteins) that are also derived from an alphavirus, such as described in Pushko et al. [Virology 239(2): 389-401 (1997)]. RP cannot be propagated in cell culture or animal hosts (without helper plasmids or similar components) because the replicon does not encode alphavirus structural components (e.g., capsid and viral glycoproteins).

[0083] The term "non-IAV-S" is used to modify terms such as pathogen and / or antigen (or immunogen) to indicate that the respective pathogen and / or antigen (or immunogen) is neither an IAV-S pathogen nor an IAV-S pathogen (or immunogen), and that the non-IAV-S protein antigen (or immunogen) is not derived from IAV-S.

[0084] For a given protein antigen and a pathogen or strain of the pathogen that naturally encodes it, the terms "originate from; originates from; originating from" can be used interchangeably, as used herein, to represent an unmodified and / or truncated amino acid sequence of a given protein antigen encoded by the pathogen or strain of the pathogen. The coding sequence in the nucleic acid construct of the present invention for a protein antigen derived from a pathogen may have been genetically manipulated to result in the expressed protein antigen having an amino acid sequence modification and / or truncation relative to the corresponding coding sequence of the protein antigen in the pathogen or pathogen strain (including a naturally attenuated strain) from which it is derived.

[0085] As used herein, the terms "protect", or "provide protection against", or "stimulate protective immunity against", and "help protect" do not require comprehensive protection against any signs of infection. For example, "help protect" can mean that the protective effect is sufficient so that after being challenged, the symptoms of the underlying infection can be at least alleviated, and / or one or more potential cellular, physiological or biochemical causes or mechanisms that cause the symptoms can be alleviated and / or eliminated. It should be understood that, as used herein, "mitigation" refers to the state relative to the infection, including the molecular state of the infection, and not just the physiological state of the infection.

[0086] As used herein, a "vaccine" is a composition suitable for application to animals, such as pigs (including humans in certain embodiments, and specifically not for humans in other embodiments), which comprises one or more antigens, usually in combination with a pharmaceutically acceptable carrier (such as a liquid containing water), and which, after administration to the animal, is capable of inducing a sufficiently strong immune response to at least help protect the animal from disease caused by infection with wild-type microorganisms, i.e., a strength sufficient to help prevent disease and / or prevent, ameliorate or cure disease.

[0087] As used herein, a multivalent vaccine is a vaccine comprising two or more different antigens. In a specific embodiment of this type, the multivalent vaccine stimulates the recipient's immune system against two or more different pathogens.

[0088] The terms "adjuvant" and "immunostimulant" are used interchangeably herein and are defined as one or more substances that cause stimulation of the immune system. In this context, adjuvants are used to enhance the immune response to one or more vaccine antigens / isolates. Thus, an "adjuvant" is an agent that non-specifically increases the immune response to a specific antigen, thereby reducing the amount of antigen necessary in any given vaccine and / or the frequency of injections necessary to produce a sufficient immune response to the antigen of interest. In this context, adjuvants are used to enhance the immune response to one or more vaccine antigens / isolates.

[0089] As used herein, a "non-adjuvanted vaccine" is a vaccine or multivalent vaccine that does not contain an adjuvant.

[0090] As used herein, the term "pharmaceutically acceptable" is used as an adjective to indicate that the modified noun is suitable for use in pharmaceuticals. For example, when used to describe an excipient in a pharmaceutical vaccine, it characterizes that the excipient is compatible with the other ingredients in the composition and has no adverse deleterious effects on the target recipient animal (e.g., pig).

[0091] "Parenteral administration" includes subcutaneous injection, submucosal injection, intravenous injection, intramuscular injection, intradermal injection and infusion.

[0092] As used herein, the term "antigenic fragment" for a specific protein (e.g., a protein antigen) refers to a fragment of the protein that is antigenic, i.e., is able to interact specifically with an antigen recognition molecule of the immune system (e.g., an immunoglobulin (antibody) or a T cell antigen receptor). For example, an antigenic fragment of IAV-S neuraminidase (NA) is a fragment of an antigenic NA protein. Preferably, the antigenic fragment of the present invention has an immunodominance for antibody and / or T cell receptor recognition. In a specific embodiment, an antigenic fragment for a given protein antigen is a fragment of the protein that retains at least 25% of the antigenicity of the full-length protein. In a preferred embodiment, the antigenic fragment retains at least 50% of the antigenicity of the full-length protein. In a more preferred embodiment, the antigenic fragment retains at least 75% of the antigenicity of the full-length protein. The antigenic fragment can be as small as 20 amino acids, or at the other extreme, it is a large fragment that is only missing one amino acid in the full-length protein. In a specific embodiment, the antigenic fragment comprises 25 to 150 amino acid residues. In other embodiments, the antigenic fragment comprises 50 to 250 amino acid residues.

[0093] As used herein, an amino acid sequence is 100% "identical" or has 100% "identity" to another amino acid sequence when the amino acid residues of the two sequences are the same. Thus, an amino acid sequence is 50% "identical" to another amino acid sequence when 50% of the amino acid residues of the two amino acid sequences are identical. Sequence comparisons are performed on contiguous blocks of amino acid residues comprised by a given protein (e.g., a portion of the protein or polypeptide being compared). In a specific embodiment, selected deletions or insertions that may alter the correspondence between two amino acid sequences are contemplated.

[0094] As used in this article, C, MacVector (MacVector, Inc. Cary, NC 27519), Vector NTI (Informax, Inc. MD), Oxford Molecular Group PLC (1996) and Clustal W algorithms can be used to determine the identity percentage of nucleotide and amino acid sequences using default comparison parameters and default parameters for identity. These commercially available programs can also be used to determine sequence similarity using the same or similar default parameters. Alternatively, advanced Blast searches under default filter conditions can be used, such as GCG (Genetics Computer Group, GCG Software Package Program Manual, 7th Edition, Madison, Wisconsin) accumulation programs using default parameters.

[0095] As used herein, the term "inactivated" microorganism is used interchangeably with "killed" microorganism. For the purposes of the present invention, an "inactivated" microorganism is an organism that is capable of stimulating an immune response in an animal, but is incapable of infecting the animal. The antigens of the present invention (e.g., inactivated Mycoplasma hyopneumoniae) may be inactivated using an agent selected from the group consisting of diethyleneimine, formalin, β-propiolactone, thimerosal, or heating. In a specific embodiment, the combination of inactivated Mycoplasma hyopneumoniae and the RP of the present invention is inactivated using diethyleneimine.

[0096] The present invention also provides vaccines against a variety of porcine pathogens. For example, the coding sequence of a protein antigen or antigenic fragment thereof for a porcine vaccine, or a combination of such protein antigen coding sequences, can be added to an alphavirus RNA replicon particle (RP) and / or combined in the same RP as the RP encoding the NA derived from IAV-S in the vaccine. Examples of pathogens that can be a source of one or more protein antigens or antigenic fragments thereof include porcine reproductive and respiratory syndrome virus (PRRS), porcine circovirus (PCV), transmissible gastroenteritis virus (TGE), pseudorabies virus (PPRV), porcine parvovirus (PPV), porcine rotavirus (PRV), porcine epidemic diarrhea virus (PED), multiple serotypes of Pasteurella multocida, Salmonella species, Escherichia coli, e.g. (serotypes K99, K88, 987P or F41), Haemophilus parasuis, Lawsonia intracellularis, Mycoplasma species (e.g., Mycoplasma hyopneumoniae), Bordetella bronchiseptica, Erysipelothrix species, Campylobacter species, Actinobacillus pleuropneumoniae, Clostridium perfringens, and Clostridium difficile.

[0097] In addition, the present invention provides vaccines comprising one or more RPs of the present invention in combination with one or more other vectors encoding one or more of these porcine antigens (e.g., baculovirus vectors encoding ORF-2 proteins from porcine circovirus-2 (PCV-2) and / or porcine circovirus-3 (PCV-3)) and / or inactivated toxoids derived from one or more of these porcine pathogens. In addition, such vaccines may include any alphavirus RNA replicon particles encoding the NA derived from IAV-S in the vaccine of the present invention, as well as one or more killed and / or modified (attenuated) live porcine virus isolates and / or porcine bacteria. All such multivalent vaccines are included in the present invention.

[0098] Thus, one or more alphavirus RNA replicon particles (RP) encoding one or more NAs derived from IAV-S may be added together with one or more other vectors encoding: one or more porcine antigens and / or one or more killed and / or modified (attenuated) live virus isolates, such as one or more killed or modified live IAS-V strains, one or more killed and / or modified live PRRS viruses, one or more killed and / or modified live PCVs, one or more killed and / or modified live TGEs, one or more killed and / or modified live PPRVs, one or more killed and / or modified live PPVs, one or more killed and / or modified live PRVs and one or more killed and / or modified live PEDs. In addition, one or more alphavirus RNA replicon particles (RP) encoding one or more NAs derived from IAV-S can be added together with one or more other vectors encoding one or more porcine antigens and / or with one or more killed and / or modified (attenuated) live bacteria that are also capable of infecting pigs, including one or more killed and / or modified live Pasteurella multocida (one or more of multiple serotypes), Salmonella species, Escherichia coli (one or more of multiple serotypes), Haemophilus parasuis, Lawsonia intracellularis, Mycoplasma species (e.g., Mycoplasma hyopneumoniae), Bordetella bronchiseptica, Erysipelothrix species, Campylobacter species, Actinobacillus pleuropneumoniae, Clostridium perfringens, and Clostridium difficile.

[0099] The alphavirus RNA replicon particles of the invention can be lyophilized and rehydrated with a sterile aqueous diluent. On the other hand, when the alphavirus RNA replicon particles are stored separately but are intended to be mixed with other vaccine components before administration, the alphavirus RNA replicon particles can be stored in a stable solution of those components (e.g., a high sucrose solution).

[0100] In one aspect, the vaccine of the present invention may include an adjuvant. In certain embodiments, the adjuvant is a biodegradable oil. In a specific formulation, the biodegradable oil is dl-α-tocopheryl acetate (vitamin E acetate). In other formulations, the adjuvant comprises an oil-in-water emulsion containing 2.5% to 50% (v / v) mineral oil. In a more specific formulation, the adjuvant comprises an oil-in-water emulsion containing 5% to 25% mineral oil. In a related formulation, the adjuvant is a mixture of two components. The first component consists of mineral oil droplets of an average size (by volume) of about 1 μm, which are stabilized using a polysorbate 80 (polyoxyethylene (20) sorbitan monooleate) aqueous solution. The first component may include 25% by weight mineral oil and 1% by weight polysorbate 80, with the remainder being water. The second component may consist of biodegradable dl-α-tocopheryl acetate droplets of approximately an average size (by volume) of about 400 nm, which are also stabilized using polysorbate 80. A specific formulation comprises 15 wt% dl-α-tocopheryl acetate and 6 wt% polysorbate 80, with the balance being water. In a specific embodiment, the adjuvant is X-SOLVE TM (It is a combination of two component adjuvants: DILUVAC FORTE based on dl-α-tocopheryl acetate TM and MICROSOL based on light liquid paraffin TM , [see, e.g., US 8,597,662]). In a related formulation, the adjuvant contains submicron-sized oil droplets and biodegradable oil droplets, wherein the average size of the biodegradable oil droplets is different from the average size of the mineral oil droplets [see, e.g., US 9,084,768].

[0101] The vaccines of the present invention can be easily administered by any standard route, including intravenous, intramuscular, subcutaneous, oral, intranasal, intradermal and / or intraperitoneal inoculation. Those skilled in the art will appreciate that the vaccine composition is preferably appropriately formulated for each type of recipient animal and route of administration.

[0102] Therefore, the present invention also provides a method for immunizing pigs against IAV-S and / or other pig pathogens. One such method includes injecting an immunologically effective amount of the vaccine of the present invention into a pig so that the pig produces appropriate IAV-S antibodies.

[0103] It should also be understood that the present invention is not limited to the specific configurations, process steps and materials disclosed herein, as such configurations, process steps and materials may vary. It should also be understood that the terminology employed herein is only for the purpose of describing specific embodiments and is not intended to limit the present invention, as the scope of the present invention will be limited only by the appended claims and their equivalents.

[0104] Sequence Listing 1

[0105]

[0106] 1 The nucleotide sequences are provided only as DNA sequences, but it will be appreciated that when the sequences are included in RNA constructs, the corresponding RNA sequences should be used (with uracil "u" ​​replacing thymine "t").

[0107]

[0108]

[0109]

[0110]

[0111]

[0112]

[0113] The following examples are intended to provide a further understanding of the present invention, but are not intended to limit the effective scope of the present invention in any way.

[0114] Example

[0115] Example 1

[0116] Efficacy of an unadjuvanted multivalent NA-RP vaccine containing four individual NA-RP constructs in weaned piglets

[0117] Introduction

[0118] RNA viruses have been used as vectors-vehicles for introducing vaccine antigens that have been genetically engineered into their genomes. However, to date, their use has been primarily limited to integrating viral antigens into RNA viruses and then introducing the virus into a recipient host. The result is the induction of protective antibodies against the integrated viral antigens. Alphavirus RNA replicon particles have been used to encode pathogenic antigens. Such alphavirus replicon platforms have been developed from several different alphaviruses, including Venezuelan equine encephalitis virus (VEE) [Pushko et al., Virology 239:389-401 (1997)], Sindbis (SIN) [Bredenbeek et al., Journal of Virology 67:6439-6446 (1993), the entire contents of which are incorporated herein by reference] and Semliki Forest virus (SFV) [Liljestrom and Garoff, Biotechnology (NY) 9:1356-1361 (1991), the entire contents of which are incorporated herein by reference]. In addition, alphavirus RNA replicon particles are the basis for several USDA-licensed swine and poultry vaccines. These include: Porcine Epidemic Diarrhea Vaccine, RNA Particles (Product Code 19U5.P1), Swine Flu Vaccine, RNA (Product Code 19A5.D0), Avian Flu Vaccine, RNA (Product Code 1905.D0), and Prescription Products, RNA Particles (Product Code 9PP0.00).

[0119] A study was conducted to determine the efficacy and immunogenicity of a quadruple non-adjuvanted NA-RP vaccine at two dose levels. The non-adjuvanted vaccine contains four RP constructs, each encoding the NA protein of a separate, distinct contemporary USIAV-S isolate. Together, these NA genes represent the two major N1 phylogenetic clusters and two N2 clusters in the US swine population. The non-adjuvanted vaccine was administered twice intramuscularly (IM) (1 mL per dose) to weaned pigs that were seronegative for both the vaccine components and the challenge strains. The efficacy of the quadruple NA-RP vaccine was then tested against heterologous N1 (H1N1 virus) and N2 (H1N2 virus) challenge infections.

[0120] Materials and methods

[0121] Construction of NA-RP antigen:

[0122] A VEE replicon vector designed for expression of the neuraminidase (NA) gene was constructed according to previous descriptions [see US 9,441,247 B2; the contents of which are incorporated herein by reference] with the following modifications. The replicon vector "pVEK" derived from TC-83 [disclosed and described in US 9,441,247 B2] was digested with restriction endonucleases AscI and PacI. A DNA plasmid containing a codon-optimized open reading frame sequence of the N1 or N2 gene with a 5' flanking sequence (5'-GGCGCGCCGCACC-3') [SEQ ID NO: 9] and a 3' flanking sequence (5'-TTAATTAA-3') [SEQ ID NO: 10] was similarly digested with restriction endonucleases AscI and PacI (Table 1). The synthetic gene expression cassettes were then ligated into the digested pVEK vector and the resulting clones were renamed "pVHV-N1-pandemic," "pVHV-N1-classical," "pVHV-N2-2002," and "pVHV-N2-1998." The "pVHV" vector nomenclature was chosen to refer to the pVEK-derived replicon vectors containing the transgene expression cassettes cloned via the AscI and PacI sites in the multiple cloning site of pVEK.

[0123] TC-83 RNA replicon particles were prepared according to previously described methods [US9,441,247 B2 and US8,460,913 B2; the contents of which are incorporated herein by reference]. Briefly, pVHV replicon vector DNA and helper DNA plasmids were linearized with NotI restriction endonuclease prior to in vitro transcription using MegaScript T7 RNA polymerase and cap analog (Promega, Madison, WI). Importantly, the helper RNA used in the preparation lacked the VEE subgenomic promoter sequence as previously described [Kamrud et al., J Gen Virol. 91(Pt 7): 1723-1727 (2010)]. The purified RNA of the replicon and helper components were combined and mixed with a Vero cell suspension, electroporated in a 4 mm cuvette, and then placed in OptiPro SFM cell culture medium (Thermo Fisher, Waltham, MA). After overnight incubation, the alphavirus RNA replicon particles were purified, prepared with phosphate buffered saline containing 5% sucrose (w / v) and 1% porcine serum, filtered through a 0.22 micron membrane filter, and aliquoted for storage. The titer of functional RP was determined using an immunofluorescence assay on infected Vero cell monolayers. Batches of RP were identified based on the gene encoded by the packaged replicon.

[0124] Table 1

[0125] N1 and N2 genes encoded in the NA-RP construct

[0126]

[0127] Viruses: Challenge viruses were obtained from the USDA National Veterinary Services Laboratories.

[0128] A / Swine / Illinois / A01554351 / 2015 (H1N1) has an HA gene from the H1-gamma cluster and an NA gene from the N1-classical cluster.

[0129] A / Swine / Iowa / A02076654 / 2015 (H1N2) has an HA gene from the H1-δ1 cluster and an NA gene from the N2-2002A cluster.

[0130] The virus was propagated in MDCK cell culture. Confluent cells were infected for about 48 hours until a clear cytopathic effect was observed in more than 70% of the cell monolayer. At harvest, the supernatant was removed from the container and clarified by centrifugation before storing the virus at -60°C or lower.

[0131] Animals: Weaned piglets were selected from a high health herd based on serological screening to confirm the absence of HI or NI antibodies to the vaccine and challenge strains. The animals were a mix of males and females and were approximately 3 weeks old at the time of the first vaccination.

[0132] Vaccination and Challenge: The treatment groups are summarized in Table 2 below. The quadruple NA-RP vaccine was formulated at two dose levels: 10 6 copies of each RP / dose (low dose) and 10 7 The functional RP was quantified by immunofluorescence-based titer assay with copies of each RP / dose (high dose). NA-RP antigen was formulated in a stabilizer consisting of 1% porcine serum and 5% sucrose. The placebo vaccine consisted of the same stabilizer without the antigen. At 3 and 7 weeks of age, the non-adjuvanted vaccine was administered to pigs IM in a dose of 1 mL. After vaccination, the dose level was determined by back titration of the remaining vaccine material by IFA testing. Serum samples were collected on the day of the first vaccination, the day of the second vaccination, and the day of the challenge infection.

[0133] Table 2

[0134] Treatment Group

[0135]

[0136] Three weeks after the second immunization, the pigs were challenged. The challenge materials, H1N1 (H1-γ-N1-classical) and H1N2 (H1-δ1b-N2-2002A) viruses, were formulated to a target dose of 10 6.5TCID50 / pig (volume 6 mL). Challenge material was administered by intratracheal route. Challenge virus dose was confirmed by back titration of remaining challenge material. Nasal swab samples were taken from all pigs at -1, 1, 3 and 5 days after challenge.

[0137] Necropsy was performed 5 days post-challenge (DPC). Under the supervision of a licensed veterinarian, pigs were euthanized with an overdose of barbiturates at 5 DPC. Lungs were collected and observed to record the surface area of ​​each lobe affected by macroscopic lesions, thereby deriving a comprehensive lung lesion score percentage. Bronchoalveolar lavage fluid and nasal swab samples were collected from all pigs to measure viral titers. Lung sections were collected for analysis of microscopic lesions.

[0138] Immune response analysis: IAV-S-specific antibodies in porcine serum samples were determined by HI and NI assays. Sera were heat inactivated at 56°C for 30-60 minutes. For HI, sera were also treated with receptor-destroying enzymes and / or kaolin and absorbed using turkey erythrocytes to remove nonspecific lectins. HI assays were performed using turkey erythrocytes as previously described [Kitikoon et al., Methods Mol Biol 1161: 295-301 (2014)]. NI assays were performed using a previously described method [Sandbulte and Eichelberger, Methods Mol Biol 1161: 337-45 (2014)] with minor modifications. Briefly, 2-fold serial dilutions of sera were mixed with equal volumes of the expressed protein antigen on a fetuin-coated 96-well plate and incubated overnight at 37°C. Peanut agglutinin horseradish peroxidase conjugate (PNA-HRP) was added for 2 hours at room temperature to bind to the fetuin molecules stripped of sialic acid. Signals were obtained by TMB chromogenic substrate and read at 650 nm. The average optical density (OD) of the negative control without NA antigen was deducted from all wells. The OD values ​​of the test samples were then standardized in the range of 0-100%, where the average OD of the positive control wells (containing NA antigen but without serum) was defined as 100%. The NI antibody titer was defined as the highest dilution of the sample that inhibited ≥50% of the neuraminidase activity.

[0139] Lung Pathology: Macroscopic lesions (well-defined purple to plum-colored consolidations) observed outside of all lobes were recorded on grid maps of the anterior and posterior lobes. A composite score (percent lung lesions) was calculated for each pig based on the number of grids affected by lesions.

[0140] Viral shedding: Nasal swab samples and BAL fluid were serially diluted 10-fold using infection medium [Dulbecco's minimal essential medium (DMEM) supplemented with 0.3% bovine serum albumin, component V; 2 mM L-glutamine; 25 μg / mL gentamicin; 2 μg / mL pancreatin IX], and 100 μL of each dilution was added to confluent MDCK cells in 96-well plates (quadruplicate). The plates were incubated at 37°C, 5% CO2, and the supernatant of each well was observed for the presence of infectious virus after 72 hours by hemagglutinin assay. The IAV-S titer was calculated by the PCR method and expressed as Log10TCID50 / mL.

[0141] result

[0142] Immune responses of pigs vaccinated with polyvalent NA-RP, see Figures 1A-1D .

[0143] High-dose and low-dose vaccines (10 7 and 10 6 The quadruple NA-RP vaccine (10 RP copies / dose) induced functional NI antibody titers against all four NA components.

[0144] NI titers induced by high-dose vaccines were approximately 1-2 times higher.

[0145] • Pigs in the placebo vaccine group remained seronegative.

[0146] Efficacy of the quadruple NA-RP vaccine against challenge infection:

[0147] Lung lesions: see Figure 2A-2B .

[0148] H1N1 challenge infection caused 13% more lesions in the lungs of placebo-controlled pigs. Both high- and low-dose immunized treatment groups had significantly lower lung lesion scores 5 days after H1N1 challenge than the unimmunized placebo group (p<0.05). Protection against lung lesions was robust regardless of vaccine dose.

[0149] The H1N2 challenge infection caused only 3.2% lesions in the lungs of the placebo-controlled pigs. Both treatment groups had lower lung lesion scores than the unimmunized placebo group 5 days after the H1N2 challenge, with mean lung lesion scores lower than 1.1% and 1.2%, respectively, but the difference between the vaccinated groups and the placebo group was not statistically significant.

[0150] Nose loss: see Figure 3A-3B .

[0151] For all three treatment groups, H1N1 challenge virus shedding was maximal at 3 DPC.

[0152] On 5DPC, viral titers were significantly reduced in both high-dose and low-dose quadruple RP treatment groups compared with placebo control (p<0.05).

[0153] Nasal shedding of the H1N2 challenge virus was more delayed, with mean titers in the placebo group not exceeding the detection limit of the assay until 5 DPC. At 5 DPC, H1N2 virus titers were significantly reduced in the vaccinated groups at both dose levels (p<0.05).

[0154] Viruses in the lungs: See Figure 4A-4B .

[0155] The viral titers of H1N1 in the bronchoalveolar lavage fluid (BALF) collected on 5 DPC in the placebo-vaccinated group were 2 logs higher than those in either of the two groups vaccinated with quadruple (4-in-1) NA-RP, in which no positive titers were detected. This represents a statistically significant difference between the two vaccination groups (p<0.05).

[0156] The virus titers in the H1N2 challenge group showed a 2-3 log reduction between the two vaccination groups and the placebo vaccination group, which was statistically significant (p<0.05).

[0157] Summarize

[0158] H1N1 infection is a more robust challenge model with higher lung lesion scores and nasal and lung viral titers. The quadruple NA-RP vaccinated group showed statistically significant protection against H1N1 virus for lung lesion severity, nasal shedding, and BALF viral titers. Individual animals in the low-dose quadruple NA-RP vaccine group that had weaker serum NI titers (<80) were also protected. H1N2 challenge infection is a less robust model because there were fewer lung lesions in the placebo group. However, even in this group, the vaccinated group produced significant protection for nasal shedding and viral titers in the lungs. The unadjuvanted multivalent NA-RP formulation is immunogenic and shows efficacy against antigenically similar challenge NA strains.

[0159] Example 2

[0160] Efficacy of an adjuvanted quadruple NA-RP vaccine against H1N1 infection in weaned pigs with N1 antibodies at first vaccination

[0161] A study was conducted to determine the efficacy and immunogenicity of a quadruple adjuvanted NA-RP vaccine. The adjuvanted vaccine contained four RP constructs, each encoding a separate, distinct NA gene from a contemporary USIAV-S isolate. Together, these NA genes represented two N1 phylogenetic clusters (N1-classical and N1-pandemic) and two N2 clusters (N2-1998 and N2-2002). The adjuvanted vaccine was administered twice intramuscularly (IM) (1 mL per dose) to weaned pigs seropositive for N1-classical antigens at the first vaccination. The efficacy of the adjuvanted quadruple NA-RP vaccine was tested against a heterologous N1 (H1N1 virus) challenge infection.

[0162] Materials and methods

[0163] Construction of NA-RP antigen: Replication-defective RNA particles (RP) containing alphavirus replicon RNA expressing the neuraminidase (NA) gene were prepared as described in Example 1.

[0164] Table 3

[0165] N1 and N2 genes encoded in the NA-RP construct

[0166]

[0167] Viruses: Challenge virus was obtained from the USDA National Veterinary Services Laboratory. A / Swine / Illinois / A01554351 / 2015 (H1N1) has the HA gene of the H1-γ cluster and the NA gene of the N1-classical cluster. Viruses were propagated in MDCK cell culture. Confluent cells were infected for approximately 48 hours until a clear cytopathic effect was seen in more than 70% of the cell monolayer. At harvest, the supernatant was removed from the container and clarified by centrifugation before storing the virus at -0°C or below.

[0168] Animals: Weaned piglets were selected from a high health herd based on serological screening to confirm the absence of HI or NI antibodies to the vaccine and challenge strains. The animals were a mix of males and females and were approximately 3 weeks old at the time of the first vaccination.

[0169] Vaccination and Challenge: Treatment groups are summarized in Table 4. 6A 4-in-1 NA-RP vaccine was formulated with 10 copies of each RP / dose, and functional RP was quantified by immunofluorescence-based titer assay. NA-RP antigens were formulated in a stabilizer consisting of 1% porcine serum and 5% sucrose. The placebo vaccine consisted of the same stabilizer without antigen. At 3 and 7 weeks of age, the vaccine was mixed with XSolve adjuvant (1:1 v / v, 1 mL dose) and then immediately administered to pigs by the IM route. After vaccination, the remaining vaccine material was back-titrated by IFA testing to determine the dose level. Serum samples were collected on the day of the first vaccination, the day of the second vaccination, and the day of the challenge infection.

[0170] All pigs were weighed 1 day before the first vaccination, and pigs in the N1-classical antibody positive group were subcutaneously injected with a dose of 2 mL / kg of N1-classical hyperimmune serum (NI titer to N1-classical antigen was 1:2560).

[0171] Table 4

[0172] Treatment Group

[0173] (n = 10 pigs per group)

[0174]

[0175] Three weeks after the second immunization, the pigs were challenged. The challenge material H1N1 (H1-γ-N1-classic) was formulated to a target dose of 10 6.5 TCID50 / pig (volume 6 mL). Challenge material was administered by intratracheal route. Challenge virus dose was confirmed by back titration of remaining challenge material. Nasal swab samples were taken from all pigs at -1, 1, 3 and 5 days after challenge.

[0176] Necropsy was performed 5 days after challenge. Pigs were euthanized with an overdose of barbiturates at 5 DPC under the supervision of a licensed veterinarian. Lungs were collected and observed to record the surface area of ​​each lobe affected by macroscopic lesions, resulting in a comprehensive lung lesion score percentage. Bronchoalveolar lavage fluid and nasal swab samples were collected from all pigs to measure viral titers. Lung sections were collected for analysis of microscopic lesions.

[0177] Immune response analysis: IAV-S-specific antibodies in porcine serum samples were determined by NI assay. Sera were heat inactivated at 56°C for 30-60 minutes. NI assay was performed using a previously described method [Sandbulte and Eichelberger, Methods Mol Biol 1161:337-45 (2014)] with minor modifications. Briefly, 2-fold serial dilutions of sera were mixed with equal volumes of expressed protein antigens on fetuin-coated 96-well plates and incubated overnight at 37°C. Peanut agglutinin horseradish peroxidase conjugate (PNA-HRP) was added for 2 hours at room temperature to bind to fetuin molecules stripped of sialic acid. Signals were obtained by TMB chromogenic substrate and the results were read at 650 nm. The average optical density (OD) of the negative control without NA antigen was subtracted from all wells. The OD values ​​of the test samples were then normalized in the range of 0-100%, where the average OD of the positive control wells (containing NA antigen but no serum) was defined as 100%. The NI antibody titer was defined as the highest dilution of sample that inhibited ≥50% of neuraminidase activity.

[0178] Lung Pathology: Macroscopic lesions (well-demarcated purple to plum-colored consolidations) observed outside of all lobes were recorded on grid maps of the anterior and posterior lobes. A composite score (percent lung lesions) was calculated for each pig based on the number of grids affected by lesions.

[0179] Viral shedding: Nasal swab samples and BAL fluid were serially diluted 10-fold using infection medium [Dulbecco's minimal essential medium (DMEM) supplemented with 0.3% bovine serum albumin, component V; 2 mM L-glutamine; 25 μg / mL gentamicin; 2 μg / mL pancreatin IX], and 100 μL of each dilution was added to confluent MDCK cells in 96-well plates (quadruplicate). The plates were incubated at 37°C, 5% CO2, and the supernatant of each well was observed for the presence of infectious virus after 72 hours by hemagglutinin assay. The IAV-S titer was calculated by the PCR method and expressed as Log10TCID50 / mL.

[0180] result

[0181] Immune responses of pigs vaccinated with polyvalent NA-RP (see, Figure 5 )

[0182] Pigs that were passively transferred with N1-classical hyperimmune serum one day before receiving their first vaccination had N1-classical antibody titers of 40-80 at the time of vaccination.

[0183] Pigs negative for N1-classic antibodies induced approximately 3-fold higher NI titers after two vaccinations with the quadruple NA-RP vaccine containing Xsolve 50 compared to pigs positive for NI-classic antibodies at the first vaccination.

[0184] In the N1-classic negative / placebo vaccinated group, pigs remained seronegative for NI titers.

[0185] Efficacy of the quadruple NA-RP vaccine against challenge-infected lung lesions (see, Figure 6 )

[0186] When administered to pigs that had no N1-classical antibodies at the time of the first vaccination, the quadruple NA-RP vaccination was highly effective in reducing lung lesions. The percentage of lung lesions was significantly lower compared to the two placebo-vaccinated groups.

[0187] Pigs vaccinated in the presence of N1-classical NI titers also had significantly reduced lung lesions compared to the two placebo vaccinated groups.

[0188] Summarize

[0189] Vaccination of both N1-classic seropositive and seronegative pigs with quadruple adjuvant NA-RP demonstrated statistically significant protection against H1N1 virus in terms of lung lesion severity compared to the placebo-vaccinated group. When pigs were vaccinated in the presence of passively transferred N1-classic antibodies, N1-classic titer levels decreased but remained positive. Furthermore, surprisingly, the quadruple NA-RP vaccine used with Xsolve adjuvant was very immunogenic to N1-classic antigens when vaccinated in N1-classic seronegative pigs.

[0190] Example 3

[0191] Vaccine efficacy evaluation of a quadruple neuraminidase (NA) vaccine formulation with a dual NA gene RP construct

[0192] The vaccine in this study consists of two RNA particle constructs, each encoding two NA genes from contemporary IAV-S isolates from the United States. One construct has two N1 phylogenetic clusters (N1-classical and N1-pandemic) and the other has two N2 clusters (N2-1998 and N2-2002). The vaccine was formulated at different doses without the use of an adjuvant. The study objective was to determine the efficacy and immunogenicity of a quadruple NA-RP vaccine formulated at different doses against H1N2 (N2-2002) virus infection in weaned pigs that were seronegative for the vaccine components.

[0193] Materials and methods

[0194] Construction and vaccine preparation of double gene (DG) NA-RP antigen

[0195] Each construct consists of an alphavirus nonstructural protein open reading frame, a subgenomic promoter followed by a NA glycoprotein gene sequence, a gap sequence, a second subgenomic promoter sequence followed by a second NA glycoprotein gene, and finally an alphavirus untranslated region. The NA DG integrated into a single RP construct is from a swine influenza virus (SIV) isolate currently prevalent in the United States and is used to synthesize the NA gene in the plasmid vector pVHV (see Table 5). The plasmid vector pVHV is a derivative of the avirulent human vaccine strain of Venezuelan equine encephalitis virus (TC-83). The completed replicon particles were verified for sequence composition and transcribed into RNA in vitro. Each NA replicon RNA was electroporated into Vero cells together with auxiliary RNA encoding VEE capsid auxiliary protein and glycoprotein sequences, thereby packaging the NA replicon RNA into RP. A multivalent immunofluorescence assay was used to quantify functional N1 and N2-specific RPs and determine vaccine doses. The test substance was serially diluted, added to a Vero cell monolayer in a 48-well plate, and incubated at 37°C for 18-24hr. Cells were fixed and stained with primary anti-N1 or N2 antibodies followed by FITC-conjugated secondary antibodies. Individual antigen-positive cells were counted and titers were calculated in RP / mL.

[0196] Table 5

[0197] N1 and N2 genes encoded in the NA-RP construct

[0198]

[0199] Four different dose levels of the vaccine were formulated in a stabilizer consisting of monosodium glutamate, sucrose, PVP, sodium sulfate, and HEPES (see, Table 6). The placebo vaccine consisted of phosphate buffered saline (PBS) without any RP construct.

[0200] Table 6

[0201] Vaccine dosage

[0202]

[0203] Virus

[0204] The challenge virus A / swine / IL / A01475495 / 2014 (H1N2) was obtained from the USDA National Veterinary Services Laboratory. The H1N2 isolate has the HA gene of the H1-δ1 cluster and the NA gene of the N2-2002 cluster. The virus was propagated in MDCK cell culture. Confluent cells were infected for about 48 hours until a clear cytopathic effect appeared in more than 70% of the cell monolayer. At harvest, the supernatant was removed from the container and clarified by centrifugation before storing the virus at -60°C or lower.

[0205] animal

[0206] Weaned piglets were selected from a high health herd based on serological screening to confirm the absence of neuraminidase inhibitory (NI) antibodies to the vaccine and challenge strains. The animals were a mix of males and females and were approximately 3 weeks old at the time of the first vaccination.

[0207] Vaccination, challenge, and sample collection; lung pathology; viral shedding and neuraminidase inhibition (NI) assays

[0208] As described above.

[0209] result

[0210] Efficacy of the quadruple NA-DG-RP vaccine against challenge infection

[0211] Macroscopic lung lesions such as Figure 7 In the lungs of placebo-controlled pigs, H1N2 challenge infection resulted in an average of 16.7% lesions. Regardless of dose level, vaccinated pigs had an average of 3.3% or less lung lesions and were significantly less than the placebo group (p<0.0001).

[0212] Nose loss (see, Figure 8 )

[0213] At the time point before the challenge, all pigs were negative for viral shedding. At 1DPC, none of the vaccinated pigs shed virus, while one pig in the placebo group shed 102.5TCID50 / m virus. At 3DPC, pigs vaccinated with the first two highest doses (Vaccine 1 and 2) had significantly less virus in the nasal cavity compared to pigs vaccinated with placebo. At 5DPC, only the pigs vaccinated with the highest vaccine dose (Vaccine 1) had significantly less viral shedding compared to the placebo group.

[0214] Immune response to vaccination

[0215] Neuraminidase inhibition (NI) potency Fig. 9As shown in. In all vaccinated pigs, vaccines prepared at different dose levels induced seroconversion (N2-2002 titer> 40), and the highest titer was 14 days after the second vaccination. There was no significant difference in the average titer between the vaccination groups detected at 14DPV2 and -1DPC. However, it seems that the NI titer level detected is related to the vaccine dose (the higher the dose, the higher the NI titer). At all sample collection time points, the pigs in the placebo group remained seronegative.

[0216] Summarize

[0217] H1N2 infection induces higher lung lesion scores with more nasal shedding. Regardless of the vaccine dose level tested, protection is robust for lung lesions (the lowest N2-DG-RP dose is 2.5x105 RP / mL). The N2-DG-RP construct requires at least 2.5x107RP / mL levels to significantly reduce shedding in the first 5 days after attack. Two weeks after the second vaccination, all pigs had positive N22002 titers. It was observed in pigs receiving higher vaccine doses that the antibody levels detected seemed to tend to rise as the vaccine dose increased.

[0218] Example 4

[0219] Vaccine efficacy evaluation of a two-combination neuraminidase (NA) vaccine formulation with a single gene RP construct

[0220] A study was conducted to determine the efficacy and immunogenicity of five different bivalent adjuvanted NA-RP vaccines, each encoding a separate, different NA gene from a contemporary EU IAV-S isolate. Together, these NA genes represent two NA phylogenetic lineages and three N2 lineages (see, Table 7 below). The adjuvanted vaccines (1 mL per dose; 5x10 6 As shown in Table 8 below, the efficacy of the five adjuvanted NA-RP vaccines against their corresponding challenge infections was tested individually.

[0221] Materials and methods

[0222] Construction of NA-RP antigen:

[0223] Replication-defective RNA particles (RP) containing alphavirus replicon RNA expressing the neuraminidase (NA) gene were prepared as described in Example 1.

[0224] Serological reaction test:

[0225] Treatment groups are summarized in Table 8 below. Adjuvant (XSolve50) was used at 5x10 6NA-RP vaccines were formulated at a dose level of 1 RP / dose. The vaccine was administered to pigs IM at 5 and 8 weeks of age in a 1-mL dose. Serum samples were collected 2 weeks after the last vaccination to quantify NI antibody titers against heterologous influenza virus strains belonging to the respective lineages and homologous NA proteins.

[0226] Vaccination and challenge:

[0227] Each group of 9 pigs was immunized twice by the intramuscular route at 5 weeks and 8 weeks of age, respectively, using RP vaccines encoding NA antigens from two different lineages and X-Solve50 adjuvant. The placebo group consisted of 7 pigs, each of which was vaccinated with RP encoding unrelated antigens and X-solve50. Two weeks after the second vaccination, blood samples were collected from all pigs to quantitatively determine the neuraminidase inhibition (NI) antibody titers against heterologous influenza virus strains belonging to their respective lineages, and the average NI titers are shown in the table. After collecting blood samples, pigs were challenged with heterologous influenza A virus strains matched to the lineage of one of the vaccine components. The pigs were killed 3 days after the attack, 6 lung samples were collected from each pig (one for each lung lobe), and the viral load was determined using the combined lung homogenate. The value is the geometric mean of the viral titer (log10 TCID50 / mL). The data were analyzed using the Mann-Whitney U test. *The values ​​are significantly different (P<0.05) compared with the respective unvaccinated groups.

[0228] Table 7

[0229] N1 and N2 genes encoded in European NA-RP constructs

[0230]

[0231] Table 8

[0232] Treatment groups and vaccination challenge results

[0233]

[0234] result

[0235] The results of this experiment are shown in Table 8. All five NA-RP vaccines induced functional NI antibody titers in pigs against heterologous influenza virus strains belonging to the respective lineages and homologous NA proteins.

[0236] Lung samples were collected from each pig and pooled lung homogenates were used to determine viral load. Values ​​presented are geometric means of viral titers (log 10 TCID 50As is evident from Table 8, the values ​​for the vaccinated pigs were significantly different (P<0.05) compared to their respective unvaccinated groups, indicating that the NA-RP vaccine was successful in terms of viral load following infection with a heterologous virus strain.

[0237] Example 5

[0238] Determination of American phylogenetic clusters

[0239] Definition of the American Neuraminidase (NA) Cluster

[0240] US N1 Cluster:

[0241] (1) Amino acid identity in the N1 cluster

[0242] a.N1 大流行 or N-pandemic is ~97%-100% (average diversity % is 3.12%)

[0243] b.N1 经典 or N1-classic is ~95%-100% (average diversity % is 4.91%)

[0244] (2) The amino acid identity between N1 clusters is ~82% (average diversity % is 18.26%)

[0245] US N2 Cluster:

[0246] (1) Amino acid identity in the N2 cluster

[0247] a.N2 1998 or N2-1998 is ~94%-100% (average diversity % is 5.94%)

[0248] b.N2 2002 or N2-2002 is ~94%-100% (average diversity % is 6.37%)

[0249] (2) The amino acid identity between N2 clusters is ~88% (average diversity % is 11.84%)

[0250] method:

[0251] Full-length non-redundant amino acid sequences of US N1 from H1N1 and H3N1 viruses (a total of about 1,550 sequences) and US N2 from H1N2 and H3N2 viruses (a total of about 2,700 sequences) collected from 2000 to the present were downloaded from the Influenza Research Database. The intra-cluster and inter-cluster amino acid identities of US N1 and N2 data were analyzed using MEGA version 7.0.7 [see, Kumar et al., Bioinformatics 28: 2685-2686 (2012)]. The two sequences were aligned using MAFFT version 7.294b [Katoh et al., Nucleic Acids Res. 30: 3059-3066 (2002); Katoh et al., Molecular Biology and Evolution 30: 772-780 (2013)], and two independent maximum likelihood phylogenetic trees of N1 and N2 were generated in FastTree version 2.1.8 [Price et al., PLoS ONE, 5 (3) 2010: e9490]. Based on the phylogeny of N1 and N2, the N1 and N2 sequences were assigned to the four previously described NA antigenic lineages (N1 经典 、N1 大流行 、N2 1998 and N2 2002 ) [see, Nelson et al., J Virol. 86(16): 8872-8878 (2012); Anderson et al., Influenza Other RespirViruses Suppl 4: 42-51 (2013)]. Specific clusters were marked and further diversity metrics were calculated using the MEGA command line (default settings), and p-distances were calculated for intra- and inter-cluster diversity using a gamma distribution rate change (α was 0.5) and partial deletion was set to 95%.

[0252] Example 6

[0253] Determination of European pedigree

[0254] Brief introduction to EU-NA:

[0255] Similar to North America, three subtypes of influenza A virus H1N1, H3N2 and H1N2 are circulated among pigs in European swine herds. However, within each subtype, the HA and NA gene lineages vary greatly [see, Kuntz-Simon and MadecZoonoses Public Health., 56(6-7): 310-325 (2009)]. As described by Watson et al., [J. Virol., 89: 9920-9931 (2015); doi: 10.1128 / JVI.00840-15], the NA genes of European swine influenza isolates belong to four major lineages and two minor lineages. The main lineages include:

[0256] 1. A(H1N1) pandemic 2009-like N1,

[0257] 2. Eurasian avian-like N1,

[0258] 3. A / Pig / Ghent / 1 / 1984-like N2 (Ghent / 84), and

[0259] 4. A / Pig / Scotland / 410440 / 1994-like N2 (Scot / 94).

[0260] Unlike other major European lineages, the NA segment of the Scottish / 94 lineage includes four major clades of viruses circulating in European pig populations. Minor European influenza NA lineages include:

[0261] 1. A / Pig / Italy / 4675 / 2003-like N2, and

[0262] 2. Human seasonal pattern N2.

[0263] Description of the methods used to analyze the EU NA-N1 and N2 gene segments:

[0264] The amino acid sequences of the full-length NA gene of European pig isolates collected between 2005 and 2018 were retrieved from the NCBI influenza virus resource [see, Watson et al., J. Virol., 89: 9920-9931 (2015); reference 32 of doi: 10.1128 / JVI.00840-15]. The N1 and N2 sequences were aligned using the Muscle (codon) aligner with the default settings provided in MEGA X [Kumar et al., Molecular Biology and Evolution 35: 1547-1549 (2018)]. The evolutionary history was inferred by using the maximum likelihood method based on the Whelan and Goldman model [Molecular Biology and Evolution 18: 691-699 (2001)]. The phylogenetic test was performed using the bootstrap method with 250 replicates. A discrete gamma distribution was used to model evolutionary rate differences between sites [5 categories (+G, parameter = 0.7258)]. The rate variation model allowed some sites to be evolutionarily invariant {[+I], 38.08% of sites}. The analysis involved 244 amino acid sequences. All positions with site coverage less than 95% were removed. That is, less than 5% of alignment gaps, missing data, and ambiguous bases were allowed at any position. A total of 469 positions were included in the final dataset. Evolutionary analyses were performed in MEGA X [Kumar et al., Molecular Biology and Evolution 35: 1547-1549 (2018)]. N1 isolates were designated as Eurasian avian-N1-like or pandemic 2009-N1-like lineages and N2 isolates were designated as Scottish / 410440 / 1994-N2-like lineages (e.g., branch 1 or branch 2), Ghent / 1 / 1984-N2-like lineages, Italian / 4675 / 2003-N2-like lineages, or human seasonal-like N2 lineages, as previously described [Watson et al., J. Virol., 89: 9920-9931 (2015)]. Genetic identities within and between lineages were calculated using MEGA X. Subsequently, a representative strain was selected from each of the above lineages as a candidate for the vaccine.

[0265] The target sequences with the resulting ranges of variability for each lineage and / or branch are as follows:

[0266] A / swine / Italy / 179057 / 2015(H1N1) sequence with 10% variability

[0267] A / swine / Italy / 28762-3 / 2013(H1N1) sequence with 15% variability

[0268] A / swine / Italy / 248147-8 / 2015 (H3N2) sequence with 10% variability

[0269] A / swine / Italy / 129452 / 2015(H1N2) sequence with 10% variability

[0270] A / swine / England / 61470 / 2013(H1N2) sequence with 10% variability

[0271] • A / swine / Italy / 246087 / 2014 (H1N2) sequence with 10% variability.

[0272] The present invention is not limited to the scope of the specific embodiments described herein. In fact, in addition to those described herein, various modifications of the present invention will become apparent to those skilled in the art based on the foregoing description. Such modifications are intended to fall within the scope of the appended claims.

[0273] It is also to be understood that all base sizes or amino acid sizes and all molecular weight or molecular mass values ​​given for nucleic acids or polypeptides are approximate and are provided for description.

Claims

1. An immunogenic composition comprising a first alphavirus RNA replicon particle encoding a first neuraminidase (NA) or an antigenic fragment thereof and a second alphavirus RNA replicon particle encoding a second NA or an antigenic fragment thereof, provided that the immunogenic composition comprises neither swine influenza A virus (IAV-S) hemagglutinin (HA) or an antigenic fragment thereof nor a nucleotide sequence encoding the IAV-S hemagglutinin (HA) or an antigenic fragment thereof; and wherein the first NA and the second NA comprise amino acid sequences having 98% or less identity.

2. The immunogenic composition of claim 1 , wherein the first NA is derived from an IAV-S from a first phylogenetic cluster and the second NA is derived from an IAV-S from a second phylogenetic cluster, wherein the first phylogenetic cluster and the second phylogenetic cluster are different; and wherein the first phylogenetic cluster and the second phylogenetic cluster are respectively selected from the following: N1-classical cluster, N1-pandemic cluster, N2-1998 cluster, and N2-2002 cluster.

3. The immunogenic composition of claim 2, wherein the first phylogenetic cluster is selected from the group consisting of: the N1-classical cluster and the N1-pandemic cluster, and wherein the second phylogenetic cluster is selected from the group consisting of: the N2-1998 cluster and the N2-2002 cluster.

4. The immunogenic composition of claim 3, wherein the first phylogenetic cluster is the N1-classical cluster and the second phylogenetic cluster is the N2-2002 cluster.

5. The immunogenic composition of claim 2, 3 or 4, further comprising a third alphavirus RNA replicon particle encoding a third NA or an antigenic fragment thereof; wherein the third NA is derived from IAV-S from a third phylogenetic cluster; and wherein the third phylogenetic cluster is different from the first phylogenetic cluster and the second phylogenetic cluster.

6. The immunogenic composition of claim 5, further comprising a fourth alphavirus RNA replicon particle encoding a fourth NA or an antigenic fragment thereof; wherein the fourth NA is derived from an IAV-S from a fourth phylogenetic cluster; and wherein the fourth phylogenetic cluster is different from the first phylogenetic cluster, the second phylogenetic cluster, and the third phylogenetic cluster.

7. The immunogenic composition of claim 6, wherein the first phylogenetic cluster is the N1-classical cluster, the second phylogenetic cluster is the N2-2002 cluster, the third phylogenetic cluster is the N1-pandemic cluster, and the fourth phylogenetic cluster is the N2-1998 cluster.

8. The immunogenic composition of claim 1, wherein the first NA is derived from an IAV-S from a first lineage and the second NA is derived from an IAV-S from a second lineage, wherein the first lineage and the second lineage are different; and wherein the first lineage and the second lineage are respectively selected from the following: N1-pandemic (EU) lineage, N1-Eurasian avian lineage, N2-Ghent / 1984 lineage, N2-Italian / 4675 / 2003 lineage, N2-Scotland / 1994 (branch 1) lineage, and N2-Scotland / 1994 (branch 2) lineage.

9. The immunogenic composition of claim 8, wherein the first lineage is selected from the group consisting of: N1 - pandemic (EU) lineage and N1 - Eurasian avian lineage; and wherein the second lineage is selected from the group consisting of: N2 - Ghent / 1984 lineage, N2 - Italy / 4675 / 2003 lineage, N2 - Scotland / 1994 (branch 1) lineage, and N2 - Scotland / 1994 (branch 2) lineage.

10. An immunogenic composition comprising alphavirus RNA replicon particles encoding two or more neuraminidase (NA) or antigenic fragments thereof; provided that the immunogenic composition contains neither swine influenza A virus (IAV-S) hemagglutinin (HA) or antigenic fragments thereof nor a nucleotide sequence encoding the IAV-S hemagglutinin (HA) or antigenic fragments thereof; and wherein the first NA and the second NA comprise amino acid sequences having 98% or less amino acid identity.

11. The immunogenic composition of claim 10, wherein the first NA is derived from an IAV-S from a first phylogenetic cluster and the second NA is derived from an IAV-S from a second phylogenetic cluster; wherein the first phylogenetic cluster and the second phylogenetic cluster are different; and wherein the first phylogenetic cluster and the second phylogenetic cluster are respectively selected from the following: N1-classical cluster, N1-pandemic cluster, N2-1998 cluster, and N2-2002 cluster.

12. The immunogenic composition of claim 11, wherein the first phylogenetic cluster is the N2-1998 cluster and the second phylogenetic cluster is the N2-2002 cluster.

13. The immunogenic composition of claim 11, wherein the first phylogenetic cluster is the N1-classical cluster and the second phylogenetic cluster is the N1-pandemic cluster.

14. The immunogenic composition of claim 13, further comprising a second αα viral RNA replicon particle encoding a third NA or an antigenic fragment thereof and a fourth NA or an antigenic fragment thereof; wherein the third NA is derived from an IAV-S from the N2-1998 cluster and the fourth NA is derived from an IAV-S from the N2-2002 cluster.

15. The immunogenic composition of claim 10, wherein the first NA is derived from an IAV-S from a first lineage and the second NA is derived from an IAV-S from a second lineage; wherein the first lineage and the second lineage are different; and wherein the first lineage and the second lineage are respectively selected from the following: N1-pandemic (EU) lineage, N1-Eurasian avian lineage, N2-Ghent / 1984 lineage, N2-Italian / 4675 / 2003 lineage, N2-Scotland / 1994 lineage (branch 1), and N2-Scotland / 1994 lineage (branch 2).

16. The immunogenic composition of claim 15, wherein the first lineage is N1 - pandemic (EU) and the second lineage is N1 - Eurasian avian.

17. The immunogenic composition of claim 16, further comprising a second polypeptide encoding a third NA or an antigenic fragment thereof and a fourth NA or an antigenic fragment thereof. α Viral RNA replicon particles; wherein the third NA is derived from an IAV-S from a lineage selected from the group consisting of the N2-Scotland / 1994 (clade 1) lineage and the N2-Scotland / 1994 (clade 2) lineage, and Wherein the fourth NA is derived from an IAV-S from a lineage selected from the group consisting of: N2-Ghent / 1984 lineage, and N2-Italy / 4675 / 2003 lineage.

18. The immunogenic composition of claim 15, wherein the first lineage is N2-Ghent / 1984 and the second lineage is N2-Scotland / 1994, clade 2.

19. The immunogenic composition of claim 15, wherein the first lineage is N2-Italian / 4675 / 2003 and the second lineage is N2-Scottish / 1994, clade 1.

20. The immunogenic composition of claims 1-19, further comprising one or more additional alphavirus RNA replicon particles encoding one or more additional NAs or antigenic fragments thereof; wherein the one or more additional NAs are derived from IAV-S.

21. The immunogenic composition of claims 1-20, wherein each alphavirus RNA replicon particle is a Venezuelan equine encephalitis virus (VEEV) alphavirus RNA replicon particle.

22. A vaccine that helps prevent diseases caused by influenza viruses, comprising the immunogenic composition of claims 1-21, and a pharmaceutically acceptable carrier; provided that the vaccine contains neither IAV-S hemagglutinin (HA) or an antigenic fragment thereof, nor a nucleotide sequence encoding IAV-S hemagglutinin (HA) or an antigenic fragment thereof.

23. The vaccine composition according to claim 22, which is a non-adjuvanted vaccine.

24. The vaccine composition of claim 22, comprising an adjuvant selected from the group consisting of a biodegradable oil, an oil-in-water emulsion with 2.5-50% (v / v) mineral oil, and a mixture of a biodegradable oil and an oil-in-water emulsion with 2.5-50% (v / v) mineral oil.

25. The vaccine composition of claim 24, wherein the biodegradable oil is dl-alpha-tocopheryl acetate and the mineral oil is liquid paraffin.

26. A method of immunizing a pig against swine influenza A virus, comprising administering to the pig an immunologically effective amount of the vaccine of claims 22, 23, 24 and 25.

Citation Information

Patent Citations

  • Apparatus and process for electrolysis using a cation-permselective membrane and turbulence inducing means

    EP0002009A1

  • Light utility vehicle chassis

    EP1069030A1

  • Promoterless cassettes for expression of alpha virus structural proteins

    US8460913B2

  • Vaccine for protection against Lawsonia intracellularis

    US8597662B2

  • Vaccine for protection against Lawsonia intracellularis, Mycoplasma hyopneumoniae and Porcine circo virus

    US9084768B2